Ryoji Fukushima

Faculty of Health and Medical Science,Department of Health and DieteticsChair of Department/Professor
Graduate School of Health Sciences,Doctoral Program in Health SciencesProfessor
Graduate School of Health Sciences,Master's and Doctoral Programs in Health and DieteticsProfessor
Last Updated :2025/10/07

■Researcher basic information

Degree

  • (BLANK), The University of Tokyo

Field Of Study

  • Life sciences, Digestive surgery
  • Life sciences, General surgery, pediatric surgery

■Career

Career

  • 2020 - Present
    Teikyo Heisei University, Faculty of Health and Medical Science Department of Health and Dietetics, Professor and Chairman
  • 2006 - 2022
    Teikyo University, School of Medicine, Professor
  • 2003 - 2006
    Teikyo University, School of Medicine, Associate Professor
  • 1995 - 2003
    Teikyo University, School of Medicine, Assistant Professor
  • 1992 - 1995
    University of Tokyo, School of Medicine, Assistant
  • 1990 - 1992
    University of Cincinnati, Research Fellow
  • 1987 - 1990
    University of Tokyo, School of Medicine, Medical Staff

Educational Background

  • 1983, Hokkaido University, School of Medicine
  • 1983, Hokkaido University, Faculty of Medicine

Member History

  • Present
  • Present
  • Present
  • Present
  • Present
  • Present
  • Present
  • Present
  • Present
  • Present
  • Present

■Research activity information

Paper

  • GLIM consensus approach to diagnosis of malnutrition: A 5-year update.
    Gordon L Jensen; Tommy Cederholm; M Isabel T D Correia; M Cristina Gonzalez; Ryoji Fukushima; Veeradej Pisprasert; Renee Blaauw; Diana Cardenas Braz; Fernando Carrasco; Alfonso J Cruz Jentoft; Cristina Cuerda; David C Evans; Vanessa Fuchs-Tarlovsky; Leah Gramlich; Han Ping Shi; Jeanette M Hasse; Michael Hiesmayr; Naoki Hiki; Harriët Jager-Wittenaar; Shukri Jahit; Anayanet Jáquez; Heather Keller; Stanislaw Klek; Ainsley Malone; Kris M Mogensen; Naoharu Mori; Manpreet Mundi; Maurizio Muscaritoli; Doris Ng; Ibolya Nyulasi; Matthias Pirlich; Stephane Schneider; Marian de van der Schueren; Soranit Siltharm; Pierre Singer; Alison Steiber; Kelly A Tappenden; Jianchun Yu; André van Gossum; Jaw-Yuan Wang; Marion F Winkler; Charlene Compher; Rocco Barazzoni
    JPEN. Journal of parenteral and enteral nutrition, 14 Apr. 2025
    BACKGROUND: The Global Leadership Initiative on Malnutrition (GLIM) introduced an approach for malnutrition diagnosis in 2019 that comprised screening followed by assessment of three phenotypic criteria (weight loss, low body mass index [BMI], and low muscle mass) and two etiologic criteria (reduced food intake/assimilation and inflammation/disease burden). This planned update reconsiders the GLIM framework based on published knowledge and experience over the past 5 years. METHODS: A working group (n = 43 members) conducted a literature search spanning 2019-2024 using the keywords "Global Leadership Initiative on Malnutrition or GLIM." Prior GLIM guidance activities for using the criteria on muscle mass and inflammation were reviewed. Successive rounds of revision and review were used to achieve consensus. RESULTS: More than 400 scientific reports were published in peer-reviewed journals, forming the basis of 10 systematic reviews, some including meta-analyses of GLIM validity that indicate strong construct and predictive validity. Limitations and future priorities are discussed. Working group findings suggest that assessment of low muscle mass should be guided by experience and available technological resources. Clinical judgment may suffice to evaluate the inflammation/disease burden etiologic criterion. No revisions of the weight loss, low BMI, or reduced food intake/assimilation criteria are suggested. After two rounds of review and revision, the working group secured 100% agreement with the conclusions reported in the 5-year update. CONCLUSION: Ongoing initiatives target priorities that include malnutrition risk screening procedures, GLIM adaptation to the intensive care setting, assessment in support of the reduced food intake/assimilation criterion, and determination of malnutrition in obesity.
  • Pembrolizumab plus cisplatin and fluorouracil as induction chemotherapy followed by definitive chemoradiotherapy for patients with cT4 and/or supraclavicular lymph node metastasis (M1Lym) of esophageal squamous cell carcinoma.
    Nobukazu Hokamura; Takeo Fukagawa; Ryoji Fukushima; Takashi Kiyokawa; Masahiro Horikawa; Yoshimasa Kumata; Yusuke Suzuki; Hironori Midorikawa
    Surgery today, Nov. 2024
    Definitive chemoradiotherapy (DCRT) is administered as standard treatment for patients with cT4 and/or M1Lym esophageal squamous cell carcinoma (ESCC); however, its long-term result is inadequate. Although several studies have reported that conversion surgery can improve the survival of these patients, none have identified significantly better long-term survival than that achieved by DCRT. Thus, enhancing DCRT seems important to improve the survival of these patients. A strategy of shrinking tumor volume before DCRT and providing consolidation chemotherapy for systemic control is expected to improve the survival of these patients. Pembrolizumab plus cisplatin and fluorouracil has demonstrated good local control and significant improvement in the survival of patients with advanced esophageal cancer. Based on these results, the following strategy is proposed: This protocol should be applied as induction for these patients; then, DCRT should be provided depending on the initial response; and finally, adjuvant chemotherapy with an immune checkpoint inhibitor should be given to all responders.
  • 【周術期感染管理のいま】胃手術における周術期感染管理               
    Oct. 2024
  • Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma.
    Nobukazu Hokamura; Takeo Fukagawa; Ryoji Fukushima; Takashi Kiyokawa; Masahiro Horikawa; Naruyoshi Soeda; Yusuke Suzuki; Shinya Kaneshiro; Koichiro Abe; Shinya Kodashima; Takatsugu Yamamoto; Yasutoshi Oshima; Tsuyoshi Ishida; Yuko Sasajima; Akihiro Nomoto; Kenshiro Shiraishi; Ai Ito
    BMC gastroenterology, 02 Sep. 2024
    BACKGROUND: Pembrolizumab plus cisplatin and 5-fluorouracil administered as first-line therapy for advanced esophageal cancer patients has shown a better objective response and survival than conventional chemotherapy with less severe hematological adverse events. The safety and efficacy of this regimen were evaluated in patients with T4b esophageal squamous cell carcinoma (ESCC). METHODS: Eight consecutive patients with T4b ESCC received this regimen according to KEYNOTE-590 as induction, and they were evaluated after 1-3 courses. The programmed death-ligand 1 (PD-L1) combined positive score (CPS) was also evaluated before chemotherapy. Efficacy for the primary lesion was evaluated by our original formula for the tumor reduction rate. RESULTS: The numbers of patients with partial response (PR), stable disease, and progressive disease (PD) were 5, 1, and 2, respectively. The tumor reduction rate ranged from 69 to 87% in PR patients, and all PR patients had relief from T4b. Two patients underwent conversion surgery with R0 resection. PD-L1 CPS was over 90 in 2 PR patients, but under 10 in 2 other PR patients. PD-L1 CPS was under 10 in PD patients. One patient had hyperprogression, resulting in an esophago-pulmonary fistula. Greater than grade 3 adverse events were bleeding gastric ulcer in one patient (12.5%), neutropenia without G-CSF in 3 patients (37.5%), and hypopotassemia in 1 patient (12.5%). No patient had febrile neutropenia. CONCLUSIONS: Marked tumor reduction was confirmed in 62.5% of patients with pembrolizumab plus cisplatin and 5-fluorouracil with less adverse events. This regimen could be administered as induction chemotherapy for patients with T4b ESCC.
  • 切除不能進行食道癌に対する1次治療としての免疫チェックポイント阻害剤併用化学療法の評価               
    Jul. 2024
  • Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: A modified Delphi approach.
    Tommy Cederholm; Gordon L Jensen; Maria D Ballesteros-Pomar; Renee Blaauw; M Isabel T D Correia; Cristina Cuerda; David C Evans; Ryoji Fukushima; Juan Bernardo Ochoa Gautier; M Cristina Gonzalez; Andre van Gossum; Leah Gramlich; Joseph Hartono; Steven B Heymsfield; Harriët Jager-Wittenaar; Renuka Jayatissa; Heather Keller; Ainsley Malone; William Manzanares; M Molly McMahon; Yolanda Mendez; Kris M Mogensen; Naoharu Mori; Maurizio Muscaritoli; Guillermo Contreras Nogales; Ibolya Nyulasi; Wendy Phillips; Matthias Pirlich; Veeradej Pisprasert; Elisabet Rothenberg; Marian de van der Schueren; Han Ping Shi; Alison Steiber; Marion F Winkler; Rocco Barazzoni; Charlene Compher
    Clinical nutrition (Edinburgh, Scotland), May 2024
    BACKGROUND & AIMS: The Global Leadership Initiative on Malnutrition (GLIM) approach to malnutrition diagnosis is based on assessment of three phenotypic (weight loss, low body mass index, and reduced skeletal muscle mass) and two etiologic (reduced food intake/assimilation and disease burden/inflammation) criteria, with diagnosis confirmed by fulfillment of any combination of at least one phenotypic and at least one etiologic criterion. The original GLIM description provided limited guidance regarding assessment of inflammation and this has been a factor impeding further implementation of the GLIM criteria. We now seek to provide practical guidance for assessment of inflammation in support of the etiologic criterion for inflammation. METHODS: A GLIM-constituted working group with 36 participants developed consensus-based guidance through a modified-Delphi review. A multi-round review and revision process served to develop seven guidance statements. RESULTS: The final round of review was highly favorable with 99 % overall "agree" or "strongly agree" responses. The presence of acute or chronic disease, infection or injury that is usually associated with inflammatory activity may be used to fulfill the GLIM disease burden/inflammation criterion, without the need for laboratory confirmation. However, we recommend that recognition of underlying medical conditions commonly associated with inflammation be supported by C-reactive protein (CRP) measurements when the contribution of inflammatory components is uncertain. Interpretation of CRP requires that consideration be given to the method, reference values, and units (mg/dL or mg/L) for the clinical laboratory that is being used. CONCLUSION: Confirmation of inflammation should be guided by clinical judgement based upon underlying diagnosis or condition, clinical signs, or CRP.
  • 当科におけるPembrolizumab+CF療法を用いたcT4/T3br食道癌に対する治療戦略               
    Apr. 2024
  • 胃全摘術後における周術期の栄養サポートチーム(NST)介入の意義               
    Apr. 2024
  • 胃全摘術後における周術期の栄養サポートチーム(NST)介入の意義               
    Feb. 2024
  • Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: A modified Delphi approach.
    Gordon L Jensen; Tommy Cederholm; Maria D Ballesteros-Pomar; Renee Blaauw; M Isabel T D Correia; Cristina Cuerda; David C Evans; Ryoji Fukushima; Juan Bernardo Ochoa Gautier; M Cristina Gonzalez; Andre van Gossum; Leah Gramlich; Joseph Hartono; Steven B Heymsfield; Harriët Jager-Wittenaar; Renuka Jayatissa; Heather Keller; Ainsley Malone; William Manzanares; M Molly McMahon; Yolanda Mendez; Kris M Mogensen; Naoharu Mori; Maurizio Muscaritoli; Guillermo Contreras Nogales; Ibolya Nyulasi; Wendy Phillips; Matthias Pirlich; Veeradej Pisprasert; Elisabet Rothenberg; Marian de van der Schueren; Han Ping Shi; Alison Steiber; Marion F Winkler; Charlene Compher; Rocco Barazzoni
    JPEN. Journal of parenteral and enteral nutrition, Feb. 2024
    BACKGROUND: The Global Leadership Initiative on Malnutrition (GLIM) approach to malnutrition diagnosis is based on assessment of three phenotypic (weight loss, low body mass index, and reduced skeletal muscle mass) and two etiologic (reduced food intake/assimilation and disease burden/inflammation) criteria, with diagnosis confirmed by fulfillment of any combination of at least one phenotypic and at least one etiologic criterion. The original GLIM description provided limited guidance regarding assessment of inflammation, and this has been a factor impeding further implementation of the GLIM criteria. We now seek to provide practical guidance for assessment of inflammation. METHODS: A GLIM-constituted working group with 36 participants developed consensus-based guidance through a modified Delphi review. A multiround review and revision process served to develop seven guidance statements. RESULTS: The final round of review was highly favorable, with 99% overall "agree" or "strongly agree" responses. The presence of acute or chronic disease, infection, or injury that is usually associated with inflammatory activity may be used to fulfill the GLIM disease burden/inflammation criterion, without the need for laboratory confirmation. However, we recommend that recognition of underlying medical conditions commonly associated with inflammation be supported by C-reactive protein (CRP) measurements when the contribution of inflammatory components is uncertain. Interpretation of CRP requires that consideration be given to the method, reference values, and units (milligrams per deciliter or milligram per liter) for the clinical laboratory that is being used. CONCLUSION: Confirmation of inflammation should be guided by clinical judgment based on underlying diagnosis or condition, clinical signs, or CRP.
  • Phase II Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 and Cisplatin for Gastric Cancer with Peritoneal Metastasis.
    Daisuke Kobayashi; Yasuhiro Kodera; Ryoji Fukushima; Masaru Morita; Sachio Fushida; Naoyuki Yamashita; Kozo Yoshikawa; Shugo Ueda; Hiroshi Yabusaki; Tetsuya Kusumoto; Takaaki Arigami; Akio Hidemura; Takeshi Omori; Hironori Yamaguchi; Yasuo Hirono; Yasushi Tsuji; Jeong Ho Moon; Toshihiko Tomita; Hiroshi Imamura; Koki Nakanishi; Dai Shimizu; Akihiro Hirakawa; Hironori Ishigami; Joji Kitayama
    Annals of surgical oncology, Feb. 2024
    BACKGROUND: Intraperitoneal chemotherapy is promising for gastric cancer with peritoneal metastasis. Although a phase III study failed to show a statistically significant superiority of intraperitoneal paclitaxel combined with S-1 and intravenous paclitaxel, the sensitivity analysis suggested clinical efficacy. Thus, attempts to combine intraperitoneal paclitaxel with other systemic therapies with higher efficacy have been warranted. We sought to explore the efficacy of intraperitoneal paclitaxel with S-1 and cisplatin. PATIENTS AND METHODS: Gastric cancer patients with peritoneal metastasis were enrolled in the phase II trial. In addition to the established S-1 and cisplatin regimen every 5 weeks, intraperitoneal paclitaxel was administered on days 1, 8, and 22 at a dose of 20 mg/m2. The primary endpoint was overall survival rate at 1 year after treatment initiation. Secondary endpoints were progression-free survival and toxicity. RESULTS: Fifty-three patients were enrolled and fully evaluated for efficacy and toxicity. The 1-year overall survival rate was 73.6% (95% confidence interval 59.5-83.4%), and the primary endpoint was met. The median survival time was 19.4 months (95% confidence interval, 16.1-24.6 months). The 1-year progression-free survival rate was 49.6% (95% confidence interval, 34.6-62.9%). The incidences of grade 3/4 hematological and non-hematological toxicities were 43% and 47%, respectively. The frequent grade 3/4 toxicities included neutropenia (25%), anemia (30%), diarrhea (13%), and anorexia (17%). Intraperitoneal catheter and implanted port-related complications were observed in four patients. There was one treatment-related death. CONCLUSIONS: Intraperitoneal paclitaxel combined with S-1 and cisplatin is well tolerated and active in gastric cancer patients with peritoneal metastasis.
  • 当科における80歳以上食道癌症例の治療内容の検討               
    Jan. 2024
  • 切除不能T4食道扁平上皮癌に対する導入療法としてのPembrolizumab+FP療法の評価               
    Jul. 2023
  • 切除不能進行・再発食道癌に対する治療戦略 T4/T3br食道癌に対する導入療法としてのペムブロリズマブとシスプラチン/5-FUの併用療法の評価(Evaluation of Pembrolizumab plus cisplatin and 5-FU as induction therapy for T4/T3br esophageal cancer)               
    外村 修一; 深川 剛生; 福島 亮治; 清川 貴志; 堀川 昌宏; 添田 成美; 鈴木 悠介; 金城 信哉; 大島 康利; 石田 毅; 笹島 ゆう子
    日本食道学会学術集会プログラム・抄録集, Jun. 2023
  • A comparison of the effects of anti-reflux procedures during esophagogastrostomy after proximal gastrectomy on the postoperative quality of life.
    Masaki Aizawa; Michihiro Ishida; Yasuhiro Kodera; Takashi Kanazawa; Ryoji Fukushima; Yoshimasa Akashi; Fumihiro Yoshimura; Shuichi Ota; Atsushi Oshio; Koji Nakada
    Surgery today, Feb. 2023
    PURPOSE: To investigate the postoperative quality of life (QOL) in patients with proximal gastric cancer (PGC) or esophago-gastric junction cancer, a nationwide multi-institutional study (PGSAS NEXT trial) was conducted. METHODS: Patients who had undergone radical resection more than 6 months previously were enrolled from 70 Japanese institutions between July 2018 and June 2020. The Postgastrectomy Syndrome Assessment Scale (PGSAS)-45 questionnaire was distributed to eligible patients, and responses were collected by mail. The main outcome measures of the PGSAS-45 were then calculated and compared. RESULTS: Questionnaires were retrieved from 1950 participants, and data from 300 patients who had undergone a proximal gastrectomy (PG) with esophagogastrostomy for PGC were analyzed. The mean esophageal reflux subscale value was 1.9 among the 276 patients who underwent an anti-reflux procedure, which was significantly better than the mean value (2.6) for the 21 patients who did not undergo an anti-reflux procedure (p = 0.002). The esophageal reflux subscale values were also compared among 3 major anti-reflux procedures: the double-flap technique (N = 153), the pseudo-fornix and/or His angle formation (N = 67), and fundoplication (N = 44); no statistically significant differences were observed. CONCLUSION: An anti-reflux procedure during esophagogastrostomy after PG for PGC is necessary to improve postoperative esophageal reflux symptoms, regardless of the type of procedure. TRIAL REGISTRATION: The PGSAS NEXT study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; registration number: 000032221).
  • Prognostic implications of the global leadership initiative on malnutrition criteria as a routine assessment modality for malnutrition in hospitalized patients at a university hospital.
    Naoharu Mori; Keisuke Maeda; Yasushi Fujimoto; Tomoyuki Nonogaki; Yuria Ishida; Rie Ohta; Akio Shimizu; Junko Ueshima; Ayano Nagano; Ryoji Fukushima
    Clinical nutrition (Edinburgh, Scotland), Feb. 2023
    BACKGROUND & AIMS: Few studies have examined the association between mortality and malnutrition diagnosed using the Global Leadership Initiative on Malnutrition (GLIM) criteria for routine nutritional assessment; thus, this association is not well known. We aimed to clarify the association between GLIM-defined malnutrition and mortality in a large population of hospitalized patients. METHODS: In this retrospective cohort study, we enrolled adult patients admitted to Aichi Medical University Hospital between April 2019 and March 2021, who underwent nutritional assessment using the GLIM criteria. In November 2021, we collected the following data from electronic medical records: demographic, clinical, and laboratory data upon admission; nutritional data assessed using GLIM criteria; and data on final patient outcomes. RESULTS: In this study, we included 9372 hospitalized patients who were identified to be at risk by the validated nutritional screening tools (50.6% men, median age 75.0 [67.0-82.0] years, 69.2% patients aged ≥70 years). The number of patients with no, moderate, and severe GLIM-defined malnutrition was 4145 (44.2%), 2799 (29.9%), and 2428 (25.9%), respectively. Kaplan-Meier survival curve analysis showed a significant increase in mortality with worsening nutritional status (log-rank test, P < 0.001). After adjusting for age and sex, multivariable Cox regression analysis revealed that both moderate (Hazard ratio [HR] 2.0, 95% confidence interval [CI] 1.79-2.23, P < 0.001) and severe malnutrition (HR 3.06, 95% CI 2.74-3.40, P < 0.001) were independent risk factors for mortality. Moreover, multivariable analysis showed that four of the five GLIM sub-criteria (except low body mass index) were independently associated with prognosis. CONCLUSION: Malnutrition and its severity, routinely assessed using the GLIM criteria, are associated with high mortality in hospitalized patients at nutritional risk. Further research is needed to evaluate the usefulness of the GLIM sub-criteria, including low body mass index, in these patients.
  • Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition diagnosis of malnutrition.
    Charlene Compher; Tommy Cederholm; Maria Isabel T D Correia; Maria Cristina Gonzalez; Takashi Higashiguch; Han Ping Shi; Stephan C Bischoff; Yves Boirie; Fernando Carrasco; Alfonso Cruz-Jentoft; Vanessa Fuchs-Tarlovsky; Ryoji Fukushima; Steven B Heymsfield; Marina Mourtzakis; Maurizio Muscaritoli; Kristina Norman; Ibolya Nyulasi; Veeradej Pisprasert; Carla M Prado; Marian de van der Schuren; Sadao Yoshida; Jianchun Yu; Gordon Jensen; Rocco Barazzoni
    JPEN. Journal of parenteral and enteral nutrition, Aug. 2022
    The Global Leadership Initiative on Malnutrition (GLIM) provides consensus criteria for the diagnosis of malnutrition that can be widely applied. The GLIM approach is based on the assessment of three phenotypic (weight loss, low body mass index, and low skeletal muscle mass) and two etiologic (low food intake and presence of disease with systemic inflammation) criteria, with diagnosis confirmed by any combination of one phenotypic and one etiologic criterion fulfilled. Assessment of muscle mass is less commonly performed than other phenotypic malnutrition criteria, and its interpretation may be less straightforward, particularly in settings that lack access to skilled clinical nutrition practitioners and/or to body composition methodologies. In order to promote the widespread assessment of skeletal muscle mass as an integral part of the GLIM diagnosis of malnutrition, the GLIM consortium appointed a working group to provide consensus-based guidance on assessment of skeletal muscle mass. When such methods and skills are available, quantitative assessment of muscle mass should be measured or estimated using dual-energy x-ray absorptiometry, computerized tomography, or bioelectrical impedance analysis. For settings where these resources are not available, then the use of anthropometric measures and physical examination are also endorsed. Validated ethnic- and sex-specific cutoff values for each measurement and tool are recommended when available. Measurement of skeletal muscle function is not advised as surrogate measurement of muscle mass. However, once malnutrition is diagnosed, skeletal muscle function should be investigated as a relevant component of sarcopenia and for complete nutrition assessment of persons with malnutrition.
  • Guidance for assessment of the muscle mass phenotypic criterion for the Global Leadership Initiative on Malnutrition (GLIM) diagnosis of malnutrition.
    Rocco Barazzoni; Gordon L Jensen; Maria Isabel T D Correia; Maria Cristina Gonzalez; Takashi Higashiguchi; Han Ping Shi; Stephan C Bischoff; Yves Boirie; Fernando Carrasco; Alfonso Cruz-Jentoft; Vanessa Fuchs-Tarlovsky; Ryoji Fukushima; Steve Heymsfield; Marina Mourtzakis; Maurizio Muscaritoli; Kristina Norman; Ibolya Nyulasi; Veeradej Pisprasert; Carla Prado; Marian de van der Schuren; Sadao Yoshida; Yanchun Yu; Tommy Cederholm; Charlene Compher
    Clinical nutrition (Edinburgh, Scotland), Jun. 2022
    The Global Leadership Initiative on Malnutrition (GLIM) provides consensus criteria for the diagnosis of malnutrition that can be widely applied. The GLIM approach is based on the assessment of three phenotypic (weight loss, low body mass index, and low skeletal muscle mass) and two etiologic (low food intake and presence of disease with systemic inflammation) criteria, with diagnosis confirmed by any combination of one phenotypic and one etiologic criterion fulfilled. Assessment of muscle mass is less commonly performed than other phenotypic malnutrition criteria, and its interpretation may be less straightforward, particularly in settings that lack access to skilled clinical nutrition practitioners and/or to body composition methodologies. In order to promote the widespread assessment of skeletal muscle mass as an integral part of the GLIM diagnosis of malnutrition, the GLIM consortium appointed a working group to provide consensus-based guidance on assessment of skeletal muscle mass. When such methods and skills are available, quantitative assessment of muscle mass should be measured or estimated using dual-energy x-ray absorptiometry, computerized tomography, or bioelectrical impedance analysis. For settings where these resources are not available, then the use of anthropometric measures and physical examination are also endorsed. Validated ethnic- and sex-specific cutoff values for each measurement and tool are recommended when available. Measurement of skeletal muscle function is not advised as surrogate measurement of muscle mass. However, once malnutrition is diagnosed, skeletal muscle function should be investigated as a relevant component of sarcopenia and for complete nutrition assessment of persons with malnutrition.
  • Accuracy of preoperative staging of gastric stump cancer.
    Takashi Kiyokawa; Takeo Fukagawa; Shinya Kaneshiro; Yuuichi Igarashi; Naruyoshi Soeda; Yoshimasa Kumata; Masahiro Horikawa; Yuko Sasajima; Keiji Matsuda; Ryoji Fukushima
    Japanese journal of clinical oncology, 31 May 2022
    BACKGROUND: In this study, the accuracy of preoperative staging for gastric stump cancer, which has not been thoroughly investigated since the condition is rare, was investigated using computed tomography and gastroscopic imaging. METHODS: Between February 1994 and April 2018, 49 patients with gastric stump cancer, following subtotal or total gastrectomy, were reviewed retrospectively. Preoperative diagnoses of clinical T and clinical N categories were compared with post-operative pathological diagnoses (pT and pN categories). Positive predictive values, accuracy, sensitivity and specificity were also evaluated. RESULTS: The overall accuracy of T staging was 40.8%. The positive predictive value for cT3/T4 was 96.3%, whereas the positive predictive value for cT1/T2 was 72.7%. The overall accuracy for N staging was 61.2%. The positive predictive value of lymph node positive patients was 73.3%. The positive predictive value and sensitivity of over stage II were 96.6% and 84.8%, respectively. CONCLUSIONS: The accuracy of preoperative diagnosis using both computed tomography and gastroscopy imaging may be feasible for T3/T4 advanced gastric stump cancer, whereas diagnosing T1/2 gastric stump cancer must be carefully considered due to high misdiagnosis rates, relating to depth.
  • 胃癌腹膜再発予測マーカーとしての血漿エクソソームmicroRNAの有用性               
    Mar. 2022
  • QOL assessment after palliative surgery for malignant bowel obstruction caused by peritoneal dissemination of gastric cancer: a prospective multicenter observational study.
    Yuichi Ito; Kazumasa Fujitani; Kentaro Sakamaki; Masahiko Ando; Ryohei Kawabata; Yutaka Tanizawa; Takaki Yoshikawa; Takanobu Yamada; Motohiro Hirao; Makoto Yamada; Jun Hihara; Ryoji Fukushima; Yasuhiro Choda; Yasuhiro Kodera; Shin Teshima; Hisashi Shinohara; Masato Kondo
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, Sep. 2021
    BACKGROUND: Patients with peritoneal dissemination of gastric cancer have poor oral intake caused by malignant bowel obstruction (MBO). Palliative surgery has often been undertaken to improve quality of life (QOL), but few prospective studies on palliative surgery in this patient population have been published. PATIENTS AND METHODS: We prospectively investigated the significance of palliative surgery using patient-reported QOL measures. Patients underwent palliative surgery by small intestine/colon resection or small intestine/colon bypass or ileostomy/colostomy for MBO. The primary endpoint was change in QOL assessed at baseline, 14 days, 1 month, and 3 months following palliative surgery using the Euro QoL Five Dimensions (EQ-5D™) questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire gastric cancer module (QLQ-STO22). Secondary endpoints were postoperative improvement in oral intake and surgical complications. RESULTS: Between April 2013 and March 2018, 63 patients were enrolled from 14 institutions. The mean EQ-5D™ utility index baseline score of 0.6 remained consistent. Gastric-specific symptoms mostly showed statistically significant improvement from baseline. Forty-two patients (67%) were able to eat solid food 2 weeks after palliative surgery and 36 patients (57%) tolerated it for 3 months. The rate of overall morbidity of ≥ grade III according to the Clavien-Dindo classification was 16% (10 patients) and the 30-day postoperative mortality rate was 3.2% (2 patients). CONCLUSIONS: In patients with MBO caused by peritoneal dissemination of gastric cancer, palliative surgery did not improve QOL while improving solid food intake, with an acceptable postoperative morbidity and mortality rate.
  • Change in antimicrobial susceptibility of pathogens isolated from surgical site infections over the past decade in Japanese nation-wide surveillance study.
    Takashi Ueda; Yoshio Takesue; Tetsuya Matsumoto; Kazuhiro Tateda; Shinya Kusachi; Hiroshige Mikamo; Junko Sato; Hideaki Hanaki; Toru Mizuguchi; Keita Morikane; Minako Kobayashi; Yasushi Harihara; Shiko Seki; Yuichi Ishida; Ryoji Fukushima; Masahiro Hada; Yoichi Matsuo; Shoji Kubo; Yutaka Kimura; Hiroaki Hata; Kazuhiko Nakajima; Hiroki Ohge; Shinji Akagi; Shigeru Takeda; Yasuo Fukui; Katsunori Suzuki; Kohji Okamoto; Katsunori Yanagihara; Hideki Kawamura
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, Jul. 2021
    Inappropriate antimicrobial therapy for surgical site infections (SSIs) can lead to poor outcomes and an increased risk of antibiotic resistance. A nationwide survey was conducted in Japan from 2018 to 2019 to investigate the antimicrobial susceptibility of pathogens isolated from SSIs. The data were compared with those obtained in 2010 and 2014-2015 surveillance studies. Although the rate of detection of extended-spectrum β-lactamase producing strains of Escherichia coli was increased from 9.5% in 2010 to 23% in 2014-2015, the incidence decreased to 8.7% in 2018-2019. Although high susceptibility rates were detected to piperacillin/tazobactam (TAZ), the geometric mean MICs were substantially higher than to meropenem (2.67 vs 0.08 μg/mL). By contrast, relatively low geometric mean MICs (0.397 μg/mL) were demonstrated for ceftolozane/TAZ. Although the MRSA incidence rate decreased from 72% in the first surveillance to 53% in the second, no further decrease was detected in 2018-2019. For the Bacteroides fragilis group species, low levels of susceptibility were observed for moxifloxacin (65.3%), cefoxitin (65.3%), and clindamycin (CLDM) (38.9%). In particular, low susceptibility against cefoxitin was demonstrated in non-fragilis Bacteroides, especially B. thetaiotaomicron. By contrast, low susceptibility rates against CLDM were demonstrated in both B. fragilis and non-fragilis Bacteroides species, and a steady decrease in susceptibility throughout was observed (59.3% in 2010, 46.9% in 2014-2015, and 38.9% in 2018-2019). In conclusion, Japanese surveillance data revealed no significant lowering of antibiotic susceptibility over the past decade in organisms commonly associated from SSIs, with the exception of the B. fragilis group.
  • Comparison of effects of six main gastrectomy procedures on patients' quality of life assessed by Postgastrectomy Syndrome Assessment Scale-45.
    Koji Nakada; Yoshiyuki Kawashima; Shinichi Kinami; Ryoji Fukushima; Hiroshi Yabusaki; Akiyoshi Seshimo; Naoki Hiki; Keisuke Koeda; Mikihiro Kano; Yoshikazu Uenosono; Atsushi Oshio; Yasuhiro Kodera
    World journal of gastrointestinal surgery, 27 May 2021
    BACKGROUND: The effects of various gastrectomy procedures on the patient's quality of life (QOL) are not well understood. Thus, this nationwide multi-institutional cross-sectional study using the Postgastrectomy Syndrome Assessment Scale-45 (PGSAS-45), a well-established questionnaire designed to clarify the severity and characteristics of the postgastrectomy syndrome, was conducted. AIM: To compare the effects of six main gastrectomy procedures on the postoperative QOL. METHODS: Eligible questionnaires retrieved from 2368 patients who underwent either of six gastrectomy procedures [total gastrectomy with Roux-en-Y reconstruction (TGRY; n = 393), proximal gastrectomy (PG; n = 193), distal gastrectomy with Roux-en-Y reconstruction (DGRY; n = 475), distal gastrectomy with Billroth-I reconstruction (DGBI; n = 909), pylorus-preserving gastrectomy (PPG; n = 313), and local resection of the stomach (LR; n = 85)] were analyzed. Among the 19 main outcome measures of PGSAS-45, the severity and characteristics of postgastrectomy syndrome were compared for the aforementioned six gastrectomy procedures using analysis of means. RESULTS: TGRY and PG significantly impaired the QOL of postoperative patients. Postoperative QOL was excellent in LR (cardia and pylorus were preserved with minimal resection). In procedures removing the distal stomach, diarrhea subscale (SS) and dumping SS were less frequent in PPG than in DGBI and DGRY. However, there was no difference in the postoperative QOL between DGBI and DGRY. The most noticeable adverse effects caused by gastrectomy were meal-related distress SS, dissatisfaction at the meal, and weight loss, with significant differences among the surgical procedures. CONCLUSION: Postoperative QOL greatly differed among six gastrectomy procedures. The severity and characteristics of postgastrectomy syndrome should be considered to select gastrectomy procedures, overcome surgical shortcomings, and enhance postoperative care.
  • Nutrition education in medical schools (NEMS) project: Joining ESPEN and university point of view.               
    Cuerda C; Muscaritoli M; Krznaric Z; Pirlich M; Van Gossum A; Schneider S; Ellegard L; Fukushima R; Chourdakis M; Della Rocca C; Milovanovic D; Lember M; Arias-Diaz J; Stylianidis E; Anastasiadis K; Alunni V; Mars T; Hellerman MI; Kujundžić-Tiljak M; Irtun O; Abbasoglu O; Barazzoni R; endorsed by the; ESPEN Council
    Clinical Nutrition, May 2021
  • nutritionDay oncologyからみた日本と世界のがん患者の栄養状態および栄養管理. 学会誌 JSPEN 2021;3(1);2-10.               
    Feb. 2021
  • 食道平滑筋腫の一例               
    Dec. 2020
  • 3号液 Solution 3               
    Nov. 2020
  • 術後感染予防抗菌薬適正使用のための実践ガイドライン(追補版)               
    May 2020, [Reviewed]
  • Clinical significance of PD-L1 and PD-L2 expression in the serum of gastric cancer patients               
    Yuichi Igarashi; Takeo Fukagawa; Junko Tamura; Yusuke Suzuki; Hiroki Midorikawa; Narumi Soeda; Yoshimasa Kumata; Masahiro Horikawa; Takashi Kiyokawa; Ryoji Fukushima
    Teikyo Medical Journal, 2020
  • Perioperative management for gastrointestinal surgery after instituting interventions initiated by the Japanese Society of Surgical Metabolism and Nutrition.
    Masaki Kaibori; Go Miyata; Kengo Yoshii; Ryoji Fukushima
    Asian journal of surgery, Jan. 2020, [Reviewed]
    BACKGROUND: In 2012, the Japanese Society for Surgical Metabolism and Nutrition introduced the Essential Strategy for Early Normalization after Surgery with Patient's Excellent Satisfaction (ESSENSE) program to improve the perioperative management of gastrointestinal surgery. The ESSENSE program aimed to minimize ineffective perioperative management practices, and achieve adequate analgesia to expedite the return to work and activities of daily living. METHODS: After educating relevant facilities about the ESSENSE program in 2012, we conducted questionnaire-based surveys in selected institutions in 2013 and 2016. RESULTS: ESSENSE was implemented in 65% of the specified gastrointestinal surgical procedures in 2016. Oral fluids were discontinued >10 h before anesthesia induction by 33% and 9% of respondents in 2013 and 2016, respectively, and 2 h before anesthesia induction by 23% and 38% in 2013 and 2016, respectively. Fasting was initiated >10 h before anesthesia induction by 75% and 29% of respondents in 2013 and 2016, respectively, and 6-8 h before anesthesia induction by 20% and 60% in 2013 and 2016, respectively. Oral rehydration with a carbohydrate-containing beverage was performed 2 h preoperatively by 23% and 47% of respondents in 2013 and 2016, respectively. The median postoperative periods after which water and solids intakes were resumed were significantly shorter in 2016 than in 2013 after five surgical procedures; the exceptions were esophagectomy, laparoscopic cholecystectomy, and hepatectomy. CONCLUSIONS: There was a high level of implementation of the ESSENSE program in participating institutions in 2016, suggesting that it is possible to achieve widespread implementation of a preoperative management protocol.
  • 【これで困らない!嚥下・栄養・離床まるわかりガイド】外科手術後の早期経腸栄養と早期経口栄養どちらを優先すべきか.               
    Jan. 2020, [Reviewed]
  • Plasma exosome-encapsulated microRNA-21 and microRNA-92a are promising biomarkers for the prediction of peritoneal recurrence in patients with gastric cancer.
    Naruyoshi Soeda; Hisae Iinuma; Yusuke Suzuki; Daisuke Tsukahara; Hironori Midorikawa; Yuichi Igarashi; Yoshimasa Kumata; Masahiro Horikawa; Takashi Kiyokawa; Takeo Fukagawa; Ryoji Fukushima
    Oncology letters, Nov. 2019, [Reviewed]
    In patients with gastric cancer (GC), peritoneal recurrence is a common risk and associated with poor prognosis. A novel biomarker for the prediction of high-risk peritoneal recurrence in patients with GC is desirable. The present study investigated the effectiveness of exosome-encapsulated microRNAs (ex-miRNAs) as minimally invasive biomarkers in patients with GC that received curative surgery. Recurrence-specific ex-miRNAs were selected following comparison of miRNA microarray data from patients with TNM stage II GC with peritoneal recurrence (n=3) and without peritoneal recurrence following curative surgery (n=3), and three healthy volunteers. In this analysis, exosome-encapsulated miRNA-21 (ex-miR-21) and exosomal miR-92a (ex-miR-92a) exhibited the greatest alterations in expression patterns. Using plasma exosome samples collected from another 129 patients with stage II and III GC, the present study investigated the potential value of ex-miR-21 and ex-miR-92a as biomarkers. Ex-miRNA levels were measured using TaqMan miRNA assays. Ex-miR-21 levels were significantly higher and ex-miR-92a levels were significantly lower in samples from patients with GC compared with healthy controls. The overall survival (OS) and peritoneal recurrence-free survival (PRFS) were poorer in stage II and III patients with high ex-miR-21 levels than in patients with low miR-21 levels. OS and PRFS of stage II and III patients with low ex-miR92a levels were significantly worse than those with high ex-miR92a levels. Cox multivariate analyses indicated that ex-miR-21 and ex-miR-92a were independent prognostic factors for OS and PRFS in stage II and III GC. A negative correlation was detected between expression levels of miR-21 and programmed cell death protein 4 mRNA, and miR-92a and prostaglandin E receptor 4 mRNA. Therefore, ex-miR-21 and ex-miR-92a may function as effective and minimally invasive biomarkers for the prediction of peritoneal recurrence and the prognosis of patients with stage II/III GC.
  • Response to the;lette;Comment on;GLIM criteria for;the;diagnosis of malnutrition;A consensus report;from the global clinical nutrition community". Some considerations about;the GLIM criteria;A consensus report for the diagnosis of malnutrition by;Drs. LB;da Silva Passos;DA De-Souza               
    Cederholm T; Compher C; Correia M; Gonzalez MC; Fukushima R; Higashiguchi T; Van Gossum A; Jensen GL
    Clinical Nutrition, Jun. 2019, [Reviewed]
  • GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community
    T. Cederholm; G.L. Jensen; M.I.T.D. Correia; M.C. Gonzalez; R. Fukushima; T. Higashiguchi; G. Baptista; R. Barazzoni; R. Blaauw; A.J.S. Coats; A.N. Crivelli; D.C. Evans; L. Gramlich; V. Fuchs‐Tarlovsky; H. Keller; L. Llido; A. Malone; K.M. Mogensen; J.E. Morley; M. Muscaritoli; I. Nyulasi; M. Pirlich; V. Pisprasert; M.A.E. de van der Schueren; S. Siltharm; P. Singer; K. Tappenden; N. Velasco; D. Waitzberg; P. Yamwong; J. Yu; A. Van Gossum; C. Compher
    Journal of Cachexia, Sarcopenia and Muscle, Feb. 2019
    Summary

    Rationale

    This initiative is focused on building a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings.

    Methods

    In January 2016, the Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. GLIM appointed a core leadership committee and a supporting working group with representatives bringing additional global diversity and expertise. Empirical consensus was reached through a series of face‐to‐face meetings, telephone conferences, and e‐mail communications.

    Results

    A two‐step approach for the malnutrition diagnosis was selected, i.e., first screening to identify “at risk” status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among the GLIM core and supporting working group members. The top five ranked criteria included three phenotypic criteria (weight loss, low body mass index, and reduced muscle mass) and two etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least one phenotypic criterion and one etiologic criterion should be present. Phenotypic metrics for grading severity as Stage 1 (moderate) and Stage 2 (severe) malnutrition are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology‐related diagnosis categories.

    Conclusion

    A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure further collaboration and endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The diagnostic construct should be re‐considered every 3–5 years.
  • GLIM criteria for the diagnosis of malnutrition – A consensus report from the global clinical nutrition community
    T. Cederholm; G.L. Jensen; M.I.T.D. Correia; M.C. Gonzalez; R. Fukushima; T. Higashiguchi; G. Baptista; R. Barazzoni; R. Blaauw; A. Coats; A. Crivelli; D.C. Evans; L. Gramlich; V. Fuchs-Tarlovsky; H. Keller; L. Llido; A. Malone; K.M. Mogensen; J.E. Morley; M. Muscaritoli; I. Nyulasi; M. Pirlich; V. Pisprasert; M.A.E. de van der Schueren; S. Siltharm; P. Singer; K. Tappenden; N. Velasco; D. Waitzberg; P. Yamwong; J. Yu; A. Van Gossum; C. Compher; Gordon L. Jensen; Compher Charlene; Tommy Cederholm; Andre Van Gossum; Maria Isabel T.D. Correia; M. Cristina Gonzalez; Ryoji Fukushima; Takashi Higashiguchi; G. Baptista; R. Barazzoni; R. Blaauw; A. Coats; A. Crivelli; D.C. Evans; L. Gramlich; V. Fuchs; H. Keller; L. Llido; A. Malone; K.M. Mogensen; J.E. Morley; M. Muscaritoli; I. Nyulasi; M. Pirlich; V. Pisprasert; M.A.E. de van der Schueren; S. Siltharm; P. Singer; K. Tappenden; N. Velasco; D. Waitzberg; P. Yamwong; J. Yu
    Clinical Nutrition, Feb. 2019
  • GLIM Criteria for the Diagnosis of Malnutrition: A Consensus Report From the Global Clinical Nutrition Community.
    Gordon L Jensen; Tommy Cederholm; M Isabel T D Correia; M Christina Gonzalez; Ryoji Fukushima; Takashi Higashiguchi; Gertrudis Adrianza de Baptista; Rocco Barazzoni; Renée Blaauw; Andrew J S Coats; Adriana Crivelli; David C Evans; Leah Gramlich; Vanessa Fuchs-Tarlovsky; Heather Keller; Luisito Llido; Ainsley Malone; Kris M Mogensen; John E Morley; Maurizio Muscaritoli; Ibolya Nyulasi; Matthias Pirlich; Veeradej Pisprasert; Marian de van der Schueren; Soranit Siltharm; Pierre Singer; Kelly A Tappenden; Nicolas Velasco; Dan L Waitzberg; Preyanuj Yamwong; Jianchun Yu; Charlene Compher; Andre Van Gossum
    JPEN. Journal of parenteral and enteral nutrition, Jan. 2019
    BACKGROUND: This initiative aims to build a global consensus around core diagnostic criteria for malnutrition in adults in clinical settings. METHODS: The Global Leadership Initiative on Malnutrition (GLIM) was convened by several of the major global clinical nutrition societies. Empirical consensus was reached through a series of face-to-face meetings, telephone conferences, and e-mail communications. RESULTS: A 2-step approach for the malnutrition diagnosis was selected, that is, first screening to identify at risk status by the use of any validated screening tool, and second, assessment for diagnosis and grading the severity of malnutrition. The malnutrition criteria for consideration were retrieved from existing approaches for screening and assessment. Potential criteria were subjected to a ballot among GLIM participants that selected 3 phenotypic criteria (non-volitional weight loss, low body mass index, and reduced muscle mass) and 2 etiologic criteria (reduced food intake or assimilation, and inflammation or disease burden). To diagnose malnutrition at least 1 phenotypic criterion and 1 etiologic criterion should be present. Phenotypic metrics for grading severity are proposed. It is recommended that the etiologic criteria be used to guide intervention and anticipated outcomes. The recommended approach supports classification of malnutrition into four etiology-related diagnosis categories. CONCLUSIONS: A consensus scheme for diagnosing malnutrition in adults in clinical settings on a global scale is proposed. Next steps are to secure endorsements from leading nutrition professional societies, to identify overlaps with syndromes like cachexia and sarcopenia, and to promote dissemination, validation studies, and feedback. The construct should be re-considered every 3-5 years.
  • 外科感染症と栄養               
    Nov. 2018, [Reviewed]
  • A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
    Kazuhiro Nishikawa; Akira Tsuburaya; Takaki Yoshikawa; Michiya Kobayashi; Junji Kawada; Ryoji Fukushima; Takanori Matsui; Kazuaki Tanabe; Kazuya Yamaguchi; Shigefumi Yoshino; Masazumi Takahashi; Naoki Hirabayashi; Seiji Sato; Hiroshi Nemoto; Yasushi Rino; Junta Nakajima; Toru Aoyama; Yohei Miyagi; Noboru Oriuchi; Kensei Yamaguchi; Yumi Miyashita; Satoshi Morita; Junichi Sakamoto
    European journal of cancer (Oxford, England : 1990), Sep. 2018, [Reviewed]
    BACKGROUND: Capecitabine plus cisplatin (XP) is a standard global regimen, while S-1 plus cisplatin (SP) is a Japanese standard for first-line treatment of advanced gastric cancer (AGC). We conducted a phase II trial comparing XP with SP for patients with AGC to confirm whether these regimens can be used as controls in a phase III study and to explore whether histological subtypes favour XP or SP. PATIENTS AND METHODS: Eligible patients were randomised to receive either S-1 40 mg/m2 for 21 days plus cisplatin 60 mg/m2 (q5w) or capecitabine 1000 mg/m2 for 14 days plus cisplatin 80 mg/m2 (q3w). The primary end-point was progression-free survival (PFS). The secondary end-points were overall survival (OS), overall response rate (ORR) and safety. RESULTS: In 110 eligible patients, 24-week PFS was higher in both groups (SP 50.9%, XP 43.5%) than the protocol-specified threshold of 40%. The median PFS for SP versus XP was 5.6 and 5.1 months (hazard ratio [HR], 1.126; p = 0.5626); OS was 13.5 and 12.6 months (HR, 0.942; p = 0.7769) and the ORR was 42.4% and 69.4% (p = 0.0237), respectively. The most common grade ≥3 adverse events with SP/XP were anaemia (16%/20%), neutropenia (9%/18%) and anorexia (18%/13%). Subgroup analysis by histological classification showed no statistical difference between treatments. CONCLUSIONS: XP and SP are comparable and can be recommended as control arms in a phase III study for AGC. Histological subtypes were not sensitive markers for the selection of XP or SP. CLINICAL TRIAL REGISTRATION: NCT00140624.
  • Exosome‑encapsulated microRNA‑23b as a minimally invasive liquid biomarker for the prediction of recurrence and prognosis of gastric cancer patients in each tumor stage.
    Yoshimasa Kumata; Hisae Iinuma; Yusuke Suzuki; Daisuke Tsukahara; Hironori Midorikawa; Yuichi Igarashi; Naruyoshi Soeda; Takashi Kiyokawa; Masahiro Horikawa; Ryoji Fukushima
    Oncology reports, Jul. 2018, [Reviewed]
  • Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.
    Hironori Ishigami; Yoshiyuki Fujiwara; Ryoji Fukushima; Atsushi Nashimoto; Hiroshi Yabusaki; Motohiro Imano; Haruhiko Imamoto; Yasuhiro Kodera; Yoshikazu Uenosono; Kenji Amagai; Shigenori Kadowaki; Hiroto Miwa; Hironori Yamaguchi; Takuhiro Yamaguchi; Tempei Miyaji; Joji Kitayama
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 01 Jul. 2018, [Reviewed]
    Purpose Intraperitoneal paclitaxel plus systemic chemotherapy demonstrated promising clinical effects in patients with gastric cancer with peritoneal metastasis. We aimed to verify its superiority over standard systemic chemotherapy in overall survival. Patients and Methods This randomized phase III trial enrolled patients with gastric cancer with peritoneal metastasis who had received no or short-term (< 2 months) chemotherapy. Patients were randomly assigned at a two-to-one ratio to receive intraperitoneal and intravenous paclitaxel plus S-1 (IP; intraperitoneal paclitaxel 20 mg/m2 and intravenous paclitaxel 50 mg/m2 on days 1 and 8 plus S-1 80 mg/m2 per day on days 1 to 14 for a 3-week cycle) or S-1 plus cisplatin (SP; S-1 80 mg/m2 per day on days 1 to 21 plus cisplatin 60 mg/m2 on day 8 for a 5-week cycle), stratified by center, previous chemotherapy, and extent of peritoneal metastasis. The primary end point was overall survival. Secondary end points were response rate, 3-year overall survival rate, and safety. Results We enrolled 183 patients and performed efficacy analyses in 164 eligible patients. Baseline characteristics were balanced between the arms, except that patients in the IP arm had significantly more ascites. The median survival times for the IP and SP arms were 17.7 and 15.2 months, respectively (hazard ratio, 0.72; 95% CI, 0.49 to 1.04; stratified log-rank P = .080). In the sensitivity analysis adjusted for baseline ascites, the hazard ratio was 0.59 (95% CI, 0.39 to 0.87; P = .008). The 3-year overall survival rate was 21.9% (95% CI, 14.9% to 29.9%) in the IP arm and 6.0% (95% CI, 1.6% to 14.9%) in the SP arm. Both regimens were well tolerated. Conclusion This trial failed to show statistical superiority of intraperitoneal paclitaxel plus systemic chemotherapy. However, the exploratory analyses suggested possible clinical benefits of intraperitoneal paclitaxel for gastric cancer.
  • Factors Influencing Cancer Patients' Choice of End-of-Life Care Place
    Maika Natsume; Kiyotaka Watanabe; Satoko Matsumoto; Daisuke Naruge; Kazuhiko Hayashi; Junji Furuse; Masafumi Kawamura; Hiromitsu Jinno; Keiji Sano; Ryoji Fukushima; Gakuji Osawa; Etsuko Aruga; Yojiro Hashiguchi; Atsushi Tanaka; Hajime Takikawa; Nobuhiko Seki
    JOURNAL OF PALLIATIVE MEDICINE, Jun. 2018
  • 糖、電解質、アミノ酸、ビタミンおよび微量元素を配合した新規中心静脈栄養輸液製剤AYF301の消化器術後患者を対象とした他施設共同比較臨床試験(第III相試験)               
    Jun. 2018, [Reviewed]
  • Two cases of early recurrence after transabdominal preperitoneal inguinal hernia repair
    Yaguchi Y; Inaba T; Kumata Y; Horikawa M; Kiyokawa T; Fukushima R
    Asian J Endosc Surg, Feb. 2018, [Reviewed]
    We performed transabdominal preperitoneal inguinal hernia repair in 46 patients (58 diseases), two of whom experienced early recurrence after mesh repair. Case 1 was a 76-year-old man with a bilateral inguinal hernia (recurrence site, left indirect hernia) after appendectomy. The recurrence occurred 1 month after transabdominal preperitoneal inguinal hernia repair. The mesh was dislocated to the lateral side, and we repaired it using the direct Kugel® patch with an anterior technique. Case 2 was a 79-year-old man with a bilateral inguinal hernia (recurrence site, right direct hernia with an orifice >3 cm) after appendectomy. The recurrence occurred 3 months after transabdominal preperitoneal inguinal hernia repair. The mesh was dislocated to the lateral side, and we repaired it using an ULTRAPRO® Plug with an anterior technique under laparoscopic observation. We believe the recurrences resulted from insufficient internal exfoliation and fixation affected by complicated exfoliation of the preperitoneal space with omental adhesion after intraperitoneal surgery.
  • 他疾患通院中の患者で検討した成人鼠径ヘルニアwatchful waitingの実態               
    稲葉 毅; 福島 亮治; 矢口 義久; 清川 貴志; 堀川 昌宏; 熊田 宣真; 添田 成美; 五十嵐 裕一
    日本ヘルニア学会誌, Jan. 2018
  • The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C).
    Kazuhiro Nishikawa; Toru Aoyama; Mari S Oba; Takaki Yoshikawa; Chu Matsuda; Yoshinori Munemoto; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoki Nagata; Motohiro Imano; Mitsuru Oshiro; Ryoji Fukushima; Masato Kataoka; Satoshi Morita; Akira Tsuburaya; Hideyuki Mishima; Toru Kono; Junichi Sakamoto
    Journal of Cancer, Apr. 2018, [Reviewed]
  • 特集 エキスパートに学ぶ栄養管理のすべて 重要患者におけるGlutamine投与の理論とエビデンス               
    Jan. 2018, [Reviewed]
  • Clinical Significance of Area of Psoas Major Muscle on Computed Tomography after Gastrectomy in Gastric Cancer Patients
    Yoshihisa Yaguchi; Yoshimasa Kumata; Masahiro Horikawa; Takashi Kiyokawa; Hisae Iinuma; Tsuyoshi Inaba; Ryoji Fukushima
    ANNALS OF NUTRITION AND METABOLISM, Jan. 2018, [Reviewed]
  • Immunonutrition               
    Sep. 2017, [Reviewed]
  • WHOの手術部位感染予防ガイドライン               
    Jul. 2017, [Reviewed]
  • 特集 最新の周術期の栄養管理 ERASと周術期栄養管理               
    Jul. 2017, [Reviewed]
  • Continuous Intraoperative Neuromonitoring Study Using Pigs for the Prevention of Mechanical Recurrent Laryngeal Nerve Injury in Esophageal Surgery
    Tomoaki Deguchi; Yoshifumi Ikeda; Masanori Niimi; Ryoji Fukushima; Masaki Kitajima
    SURGICAL INNOVATION, Apr. 2017, [Reviewed]
  • Health insurance or subsidy has universal advantage for management of hospital malnutrition unrelated to GDP
    Stanislaw Klek; Michael Chourdakis; Dima Abdulqudos Abosaleh; Alejandra Amestoy; Hyun Wook Baik; Gertrudis Baptista; Rocco Barazzoni; Ryoji Fukushima; Josef Hartono; Ranil Jayawardena; Rafael Jimenez Garcia; Zeljko Krznaric; Ibolya Nyulasi; Gabriela Parallada; Eliza Mei Perez Francisco; Marina Panisic-Sekeljic; Mario Perman; Anna Prins; Isabel Martinez del Rio Requejo; Ravinder Reddy; Pierre Singer; Marianna Sioson; Andrew Ukleja; Carla Vartanian; Nicolas Velasco Fuentes; Dan Linetzky Waitzberg; Steve Leonce Zoungrana; Aleksander Galas
    ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION, Mar. 2017, [Reviewed]
  • Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper
    Toru Aoyama; Kazuhiro Nishikawa; Mari Oba; Takaki Yoshikawa; Chu Matsuda; Yoshinori Munemoto; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoki Nagata; Motohiro Imano; Mitsuru Oshiro; Ryoji Fukushima; Masato Kataoka; Satoshi Morita; Akira Tsuburaya; Hideyuki Mishima; Toru Kono; Junichi Sakamoto
    Annals of Cancer Research and Therapy, 2017, [Reviewed]
  • Randomized clinical trial of 24 versus 72 h antimicrobial prophylaxis in patients undergoing open total gastrectomy for gastric cancer
    A. Takagane; Y. Mohri; T. Konishi; R. Fukushima; T. Noie; S. Sueyoshi; K. Omura; S. Ono; M. Kusunoki; H. Mochizuki; Y. Sumiyama
    BRITISH JOURNAL OF SURGERY, Jan. 2017, [Reviewed]
  • Sublay Flat Mesh の縫合固定は必要か?-当科で施行している固定法の紹介-               
    Dec. 2016, [Reviewed]
  • 術後感染予防抗菌薬適正使用のための実践ガイドライン               
    Mar. 2016, [Reviewed]
  • 中心静脈栄養と真菌感染               
    Feb. 2016, [Reviewed]
  • 3 ケース別 輸液管理をマスター ④感染症               
    Feb. 2016, [Reviewed]
  • Gastrointestinal metastasis of cardiac leiomyosarcoma
    Koichiro Abe; Kazunori Seo; Minami Yagi; Yuko Sasajima; Takahiro Yagi; Tsuyoshi Inaba; Ryoji Fukushima
    ENDOSCOPY, 2016, [Reviewed]
  • Large-bowel perforation caused by cytomegalovirus enteritis during long-term steroid treatment for polymyositis
    Tamuro Hayama; Yoshihisa Fukushima; Ryu Shimada; Shoichi Fujii; Keijiro Nozawa; Yuko Sasajima; Keiji Matsuda; Ryoji Fukushima; Yojiro Hashiguchi
    Japanese Journal of Gastroenterological Surgery, 2016, [Reviewed]
  • 生活習慣病と胃癌・食道癌               
    Oct. 2015, [Reviewed]
  • 注目すべき最新SSI対策-高濃度酸素投与・正常体温維持・血糖コントロール               
    Oct. 2015, [Reviewed]
  • Long-term Survival after Effective Chemoradiation Therapy on an Outpatient Basis for Stage IVa Esophageal Cancer—Report of a Case—
    TANAKA Masanao; FUKUSHIMA Ryouji
    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), Sep. 2015, [Reviewed]
    A 72-year-old woman presented with far advanced esophageal cancer with a total of four lymph nodes metastases at the abdomen and the left supraclavicular fossa. The main lesion was resectable. We decided to perform an esophagectomy without superior mediastinal and cervical lymphadenectomy to avoid excessive invasive operation and to employ postoperative chemoradiation therapy (CRT) to the region left undissected superior mediastinal metastases. In June 2006, we performed subtotal esophagectomy by right thoracotomy and laparotomy and 2-field lymph node dissection. The histopathological diagnosis was type 4 cancer of the lower thoracic esophagus, pT3, pN2 (No3, No9), pStage IVa. After the operation, she removed a jejunostomy tube by herself, for that reoperation was required and CRT could not be started, with resultant enlargement of the 104L metastasis. The patient strongly desired to receive CRT which could be done on an outpatient basis, so that we selected such a palliative therapy as gave Linac X irradiation to the 104L metastasis at a dose of 50 Gy and oral medication of TS-1 alone for 5 years. As a result, the 104L metastasis almost disappeared, and a complete response (CR) has been kept for 8 years without recurrence and metastasis.
  • Application of an eating recovery assisting food cooked soft enzyme treatment technology for the postoperative diet of gastric surgery patients:- Safety Assessment -
    Shimizu Nobuyuki; Hatao Fumihiko; Fukatsu Kazuhiko; Ootani Sachiko; Sekine Rie; Asakura Hitomi; Okamoto Tomoko; Inaba Tsuyoshi; Shibata Chikashi; Fukushima Ryoji; Sasaki Iwao; Seto Yasuyuki
    The Japanese Journal of SURGICAL METABOLISM and NUTRITION, Aug. 2015, [Reviewed]
    Recently, nutritional care that shortens the fasting duration has been performed during the perioperative period and numerous studies on the early resumption of oral intake have been reported. However, evaluations to explore suitable meals for advancing the start of oral intake have not been undertaken. For food intake recovery support meals (hereinafter referred to as postoperative diet I-III) used in this study, the softness of the meal is adjusted to the same level as the difficulty of mastication for the patient consuming the meal using a method which is based on enzyme treatment technology.
    The burden on the gastrointestinal tract of postoperative diet I-III in early post-operative patients is low, and since the appearance of the meal is similar to normal meals, an increase in the appetite of patients was expected.
    This study targeted patients between the ages of 20 and 75 years old who underwent total gastrectomy and were able to eat postoperative diet provided by the hospital from postoperative day 4. Patients were sequentially provided 6 meals of postoperative diet I-III with 3 different NPC/N ratios from postoperative days 4 to 9. Information such as food intake rate, subjective and objective opinions, and clinical laboratory data were collected.
    In this study, since no adverse events were observed after consuming postoperative diet I-III, the safety of these meals after gastrectomy was demonstrated.
  • 外科周術期管理の最前線―術後回復力強化プログラム 1. 特集によせて―術後回復力強化プログラムの概要―               
    Jul. 2015, [Reviewed]
  • 周術期の血糖管理               
    May 2015, [Reviewed]
  • 入院編 感染症のために予定手術を延期した患者が手術を受けられるまでの期間に目安があるってホント?               
    May 2015, [Reviewed]
  • 経腸栄養 早期経腸栄養の意義と適応               
    May 2015, [Reviewed]
  • 外科侵襲と栄養管理               
    Apr. 2015, [Reviewed]
  • 魚骨による消化管穿孔3例の経験               
    Feb. 2015
  • 海外文献紹介 ICU患者における感染症発生に対する、高蛋白免疫調整経腸栄養剤と高蛋白標準経腸栄養剤の無作為化比較試験(MetaPlus試験の結果報告). Van Zanten AR, et al. JAMA 312:514-524,2014               
    Feb. 2015, [Reviewed]
  • 回復力強化プログラム               
    Jan. 2015, [Reviewed]
  • 感染管理・栄養管理の鉄則 感染管理               
    Jan. 2015, [Reviewed]
  • PK-PDパラメータを活用した感染症治療の実際 外科手術感染症               
    Dec. 2014, [Reviewed]
  • Evaluation of QOL After Proximal Gastrectomy Using a Newly Developed Assessment Scale (PGSAS-45)
    Takao Inada; Masashi Yoshida; Masami Ikeda; Takeyoshi Yumiba; Hideo Matsumoto; Akinori Takagane; Chikara Kunisaki; Ryoji Fukushima; Hiroshi Yabusaki; Koji Nakada
    WORLD JOURNAL OF SURGERY, Dec. 2014, [Reviewed]
  • 鼠径ヘルニア術野における知覚神経の走行に関する検討               
    Nov. 2014, [Reviewed]
  • 海外文献紹介 術後回復力強化(ERAS)プログラムの有効性を評価する指標に関するシステマティックレビュー. Neville A. et al. Br.J.Surg.101:159-170.2014               
    Nov. 2014, [Reviewed]
  • 福島亮治:Editorial 臨床試験とエビデンス               
    Nov. 2014, [Reviewed]
  • Efficacy and Safety Evaluation of a Novel Enteral Nutrition Formula (ENG-J) in Postoperative Patients who Underwent Esophagectomy or Total Gastrectomy for Cancer —A Multicenter Randomized Open-Label, Unblinded Parallel Comparative Study—
    Fukushima Ryoji; Yano Masahiko; Ikejiri Koji; Mochizuki Izumi; Nomura Takashi; Nakagawa Satoru; Ogoshi Kyoji; Takagi Masakazu
    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), Oct. 2014, [Reviewed]
    Purpose : The purpose of this study was to compare the efficacy and safety of the new enteral nutrition formula ENG-J with a standard enteral nutrition formula Racol®liquid (control) in postoperative patients who underwent esophagectomy or total gastrectomy. Subjects and Methods : This is a multi-center prospective randomized open-label parallel study. Esophageal or gastric cancer patients (N=117) who underwent esophagectomy or total gastrectomy were recruited. Patients were randomly assigned to receive either ENG-J or control via feeding tube starting on postoperative day 3 and administration was continued for 10 days. Efficacy and safety were assessed through measurement of nutritional status and monitoring of adverse events. Result : Fifty-nine patients received ENG-J and 58 patients received control. Intent-To-Treat analysis was done on 59 patients in ENG-J group and 57 patients in control group. There was no difference in nutrition status assessed by RTP (rapid turnover protein), serum total protein, serum albumin,and NI (nutrition index) between ENG-J and control groups. Incidence of adverse events was similar between the two groups. Gastrointestinal disorder was the most frequent type of adverse events in the both groups. Conclusion : ENG-J is an efficacious and safe enteral nutrition formula suitable for postoperative patients.
  • 進行胃癌に対する集学的治療-腹膜播種に対する治療戦略-               
    Oct. 2014, [Reviewed]
  • 感染症診療 update. Ⅱ章 主要な臓器感染症 H.腹腔内感染症 細菌性腹膜炎               
    Oct. 2014, [Reviewed]
  • SCCM/ASPEN栄養管理ガイドライン               
    Aug. 2014, [Reviewed]
  • 海外文献紹介 胃癌手術患者におけるアルギニン強化経腸栄養と標準経腸栄養投与の無作為比較試験-術後7日間のアルギニン投与が胃癌の長期予後を改善する-. Zhao H et al. J.Cancer Res Cli Oncol 2013               
    Aug. 2014, [Reviewed]
  • Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
    Akira Tsuburaya; Kazuhiro Yoshida; Michiya Kobayashi; Shigefumi Yoshino; Masazumi Takahashi; Nobuhiro Takiguchi; Kazuaki Tanabe; Naoto Takahashi; Hiroshi Imamura; Naokuni Tatsumoto; Akinori Hara; Kazuhiro Nishikawa; Ryoji Fukushima; Isao Nozaki; Hiroshi Kojima; Yumi Miyashita; Koji Oba; Marc Buyse; Satoshi Morita; Junichi Sakamoto
    The Lancet. Oncology, Jul. 2014, [Reviewed]
    BACKGROUND: The prognosis for locally advanced gastric cancer is poor despite advances in adjuvant chemotherapy. We did the Stomach cancer Adjuvant Multi-Institutional group Trial (SAMIT) to assess the superiority of sequential treatment (paclitaxel then tegafur and uracil [UFT] or paclitaxel then S-1) compared with monotherapy (UFT or S-1) and also the non-inferiority of UFT compared with S-1. METHODS: We did this randomised phase 3 trial with a two-by-two factorial design at 230 hospitals in Japan. We enrolled patients aged 20-80 years with T4a or T4b gastric cancer, who had had D2 dissection and a ECOG performance score of 0-1. Patients were randomly assigned to one of four treatment groups with minimisation for tumour size, lymph node metastasis, and study site. Patients received UFT only (267 mg/m(2) per day), S-1 only (80 mg/m(2) per day) for 14 days, with a 7-day rest period or three courses of intermittent weekly paclitaxel (80 mg/m(2)) followed by either UFT, or S-1. Treatment lasted 48 weeks in monotherapy groups and 49 weeks in the sequential treatment groups. The primary endpoint was disease-free survival assessed by intention to treat. We assessed whether UFT was non-inferior to S-1 with a non-inferiority margin of 1·33. This trial was registered at UMIN Clinical Trials Registry, number C000000082. FINDINGS: We randomly assigned 1495 patients between Aug 3, 2004, and Sept 29, 2009. 374 patients were assigned to receive UFT alone, 374 to receive S-1 alone, 374 to received paclitaxel then UFT, and 373 to receive paclitaxel then S-1. We included 1433 patients in the primary analysis after at least 3 years of follow-up (359, 364, 355, and 355 in each group respectively). Protocol treatment was completed by 215 (60%) patients in the UFT group, 224 (62%) in the S-1 group, 242 (68%) in the paclitaxel then UFT group, and 250 (70%) in the paclitaxel then S-1 group. 3-year disease-free survival for monotherapy was 54·0% (95% CI 50·2-57·6) and that of sequential treatment was 57·2% (53·4-60·8; hazard ratio [HR] 0·92, 95% CI 0·80-1·07, p=0·273). 3-year disease-free survival for the UFT group was 53·0% (95% CI 49·2-56·6) and that of the S-1 group was 58·2% (54·4-61·8; HR 0·81, 95% CI 0·70-0·93, p=0·0048; pnon-inferiority=0·151). The most common grade 3-4 haematological adverse event was neutropenia (41 [11%] of 359 patients in the UFT group, 48 [13%] of 363 in the S-1 group, 46 [13%] of 355 in the paclitaxel then UFT group, and 83 [23%] of 356 in the paclitaxel then S-1 group). The most common grade 3-4 non-haematological adverse event was anorexia (21 [6%], 24 [7%], seven [2%], and 18 [5%], respectively). INTERPRETATION: Sequential treatment did not improve disease-free survival, and UFT was not non-inferior to S-1 (and S-1 was superior to UFT), therefore S-1 monotherapy should remain the standard treatment for locally advanced gastric cancer in Japan. FUNDING: Epidemiological and Clinical Research Information Network.
  • Feasibility of enhanced recovery after surgery in gastric surgery: a retrospective study
    Takanobu Yamada; Tsutomu Hayashi; Toru Aoyama; Junya Shirai; Hirohito Fujikawa; Haruhiko Cho; Takaki Yoshikawa; Yasushi Rino; Munetaka Masuda; Hideki Taniguchi; Ryoji Fukushima; Akira Tsuburaya
    BMC SURGERY, Jul. 2014, [Reviewed]
  • 【ドレーンは必要か】 術後回復強化プログラムからみたドレーン管理               
    Jul. 2014, [Reviewed]
  • 水溶性ビタミン配合新規末梢静脈栄養輸液製剤AJF102の消化器術後患者を対象とした多施設共同比較臨床試験(第III相試験)               
    Jul. 2014, [Reviewed]
  • Laparoscopic lysis for jejunostomy-related ileus following;laparoscopy-assisted total gastrectomy a case report.               
    Inoue T; Ikeda Y; Ogawa E; Horikawa M; Inaba T; Fukushima R
    Asian journal of endoscopic surgery, May 2014, [Reviewed]
  • Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis
    Toru Aoyama; Kazuhiro Nishikawa; Nobuhiro Takiguchi; Kazuaki Tanabe; Motohiro Imano; Ryoji Fukushima; Junichi Sakamoto; Mari S. Oba; Satoshi Morita; Toru Kono; Akira Tsuburaya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, May 2014, [Reviewed]
  • Recurrent Laryngeal Nerve Monitoring during Thoracoscopic Esophagectomy
    Yoshifumi Ikeda; Taisuke Inoue; Estushi Ogawa; Masahiro Horikawa; Tsuyoshi Inaba; Ryoji Fukushima
    WORLD JOURNAL OF SURGERY, Apr. 2014, [Reviewed]
  • Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
    Hisae Iinuma; Ryoji Fukushima; Tsuyoshi Inaba; Junko Tamura; Taisuke Inoue; Etsushi Ogawa; Masahiro Horikawa; Yoshibumi Ikeda; Noriyuki Matsutani; Kazuyoshi Takeda; Koji Yoshida; Takuya Tsunoda; Tadashi Ikeda; Yusuke Nakamura; Kota Okinaga
    JOURNAL OF TRANSLATIONAL MEDICINE, Apr. 2014, [Reviewed]
  • 海外文献紹介 直腸手術後の腸管麻痺が早期経腸栄養で軽減される Boelens PG et al. Ann Surg 2013.               
    Feb. 2014, [Reviewed]
  • Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial
    Takaki Yoshikawa; Kazuaki Tanabe; Kazuhiro Nishikawa; Yuichi Ito; Takanori Matsui; Yutaka Kimura; Naoki Hirabayashi; Shoki Mikata; Makoto Iwahashi; Ryoji Fukushima; Nobuhiro Takiguchi; Isao Miyashiro; Satoshi Morita; Yumi Miyashita; Aakira Tsuburaya; Junichi Sakamoto
    ANNALS OF SURGICAL ONCOLOGY, Jan. 2014, [Reviewed]
  • 【スキルアップ外来栄養食事指導】 臨床医から外来栄養食事指導に望むこと 外科医の立場から               
    Sep. 2013, [Reviewed]
  • 腹臥位食道切除術時の反回神経刺激モニターの有用性               
    Jul. 2013
  • 大学病院全外科系を対象とした周術期予防的抗菌薬の適正使用への取り組み               
    Jun. 2013, [Reviewed]
  • Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer.
    Akira Tsuburaya; Naoki Nagata; Haruhiko Cho; Naoki Hirabayashi; Michiya Kobayashi; Hiroshi Kojima; Yasuhiro Munakata; Ryoji Fukushima; Yoichi Kameda; Tadakazu Shimoda; Koji Oba; Junichi Sakamoto
    Cancer chemotherapy and pharmacology, May 2013, [Reviewed]
    PURPOSE: Paclitaxel-cisplatin (TC) combination is effective and well tolerated in patients with unresectable gastric cancer. We investigated the efficacy and safety of TC for locally advanced gastric cancers in a neoadjuvant setting. METHODS: Patients received 2-4 courses of paclitaxel (80 mg/m(2)) and cisplatin (25 mg/m(2)) on days 1, 8, and 15 in a 4-weekly schedule, followed by radical gastrectomy. Primary endpoint was the pathological response rate: percentage of tumors in which one-third or more parts were affected. RESULTS: All 52 patients enrolled were eligible. Thirty-six (69.7 %) patients completed two or more courses of chemotherapy. Forty-three patients (82.7 %) underwent surgery, 33 (63.5 %) had R0 resection, and there was no treatment-related death. The pathological response was 34.6 % (95 % CI 22.0-49.1) for all registered patients; the null hypothesis of tumor response ≤10 % was rejected (p < 0.0001). The 3-year overall survival was 41.5 % (95 % CI 27.4-55.0). CONCLUSIONS: The neoadjuvant chemotherapy with TC was safe and effective for patients with locally advanced gastric cancer, and further study is needed to confirm the effectiveness of this regimen.
  • 【実地医家のための臨床栄養update】 胃瘻の適応と実際               
    May 2013, [Reviewed]
  • 【エキスパートが本気で教える重症患者の栄養管理-知らないと痛い目をみる!?コツとピットフォール-】 病態別栄養管理 消化器外科周術期の栄養管理 手術から順調に回復するために栄養は欠かせない               
    May 2013, [Reviewed]
  • 【デバイス関連感染症防止対策】 カテーテル関連血流感染 中心静脈カテーテル               
    Apr. 2013, [Reviewed]
  • 【癌患者に対する栄養療法】 癌患者と栄養介入 栄養療法の実践 癌患者における経腸栄養法               
    Feb. 2013, [Reviewed]
  • 手術時手洗い前後の手指細菌数の検討 医師、看護師、医学生の比較               
    Feb. 2013, [Reviewed]
  • Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan
    Yoshio Takesue; Akira Watanabe; Hideaki Hanaki; Shinya Kusachi; Tetsuro Matsumoto; Aikichi Iwamoto; Kyoichi Totsuka; Keisuke Sunakawa; Morimasa Yagisawa; Junko Sato; Toyoko Oguri; Kunio Nakanishi; Yoshinobu Sumiyama; Yuko Kitagawa; Go Wakabayashi; Isamu Koyama; Katsuhiko Yanaga; Toshiro Konishi; Ryoji Fukushima; Shiko Seki; Shun Imai; Tsunehiro Shintani; Hiroki Tsukada; Kazuhiro Tsukada; Kenji Omura; Hiroshige Mikamo; Hiromitsu Takeyama; Masato Kusunoki; Shoji Kubo; Junzo Shimizu; Toshihiro Hirai; Hiroki Ohge; Akio Kadowaki; Kohji Okamoto; Katsunori Yanagihara
    JOURNAL OF INFECTION AND CHEMOTHERAPY, Dec. 2012, [Reviewed]
  • 【ICU患者の栄養管理】 免疫強化栄養               
    Dec. 2012, [Reviewed]
  • 急性炎症モデル作製法               
    Nov. 2012, [Reviewed]
  • 最近の外科周術期管理法 ERASプロトコルについて               
    Nov. 2012, [Reviewed]
  • Chronic pain and discomfort after inguinal hernia repair
    Tsuyoshi Inaba; Kota Okinaga; Ryoji Fukushima; Yoshifumi Ikeda; Eriko Yamazaki; Taihei Koide; Masahiro Horikawa; Taisuke Inoue; Etsushi Ogawa
    SURGERY TODAY, Sep. 2012, [Reviewed]
  • The Breath Test System Involving a Novel Tracer, C-13-Uracil and Wagner-Nelson Analysis: Comparison with the Gastric Emptying Scintigraphy
    Ryoji Fukushima; Taisuke Inoue; Etsushi Ogawa; Masahiro Horikawa; Eriko Yamazaki; Kota Iwasaki; Tsuyoshi Inaba; Tatsuro Kaminaga; Masaki Sanaka
    HEPATO-GASTROENTEROLOGY, Sep. 2012, [Reviewed]
  • Accurate and rapid novel genetic diagnosis for detection of sentinel lymph node metastasis in breast cancer patients
    H. Iinuma; J. Tamura; D. Omoto; N. Kamo; S. Ohnaka; Y. Mitoma; Y. Miyazawa; K. Okinaga; T. Imamura; R. Fukushima; T. Watanabe; T. Ikeda
    BRITISH JOURNAL OF CANCER, Aug. 2012, [Reviewed]
  • Nutrition Support in Surgical Wards : Difference among the Departments
    INABA Tsuyoshi; HAYASAKI Maiko; YASUTOMI Noriko; KURISHIMA Miyuki; KOYAMA Maki; KUROSAKI Tomoko; OZAKI Maiko; ISHIKAWA Kazue; ASAKURA Hitomi; FUKUSHIMA Ryoji
    Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), Aug. 2012, [Reviewed]
    Nutrition Support Team (NST) in our hospital was founded in 2006. Recently NST and pressure ulcer treatment team had been working jointly. From 2008 we have participated in the "nutritionDay" project of European Society for Clinical Nutrition and Metabolism. We report the characters of nutrition support methods in our hospital, which we learned from these activities.Patient with poor nutritional status were mainly found the departments in which most of the patients had malignant diseases or in department of neurology. Nutrition support methods differed by departments. Aggressive treatments such as early enteral nutrition or immunonutrition were mainly used in department of gastrointestinal surgery. Many patients received enteral nutrition also in department of neurosurgery. In contrast few patients were treated with enteral nutrition in department of cardiovascular surgery.In high volume hospitals it may be difficult to know the characteristics of nutrition support techniques of all departments. Joint activities with other teams or participation in worldwide studies are beneficial to solve this problem. We found that many doctors in each department established unique nutrition support techniques, which were suitable for patient characteristics. Not only to make suggestions, but also to learn these techniques may be important for NST members
  • CA19-9産生胃癌の1例
    Aug. 2012, [Reviewed]
  • Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis
    Kohei Shitara; Satoshi Morita; Kazumasa Fujitani; Shigenori Kadowaki; Nobuhiro Takiguchi; Naoki Hirabayashi; Masazumi Takahashi; Masakazu Takagi; Yukihiko Tokunaga; Ryoji Fukushima; Yasuhiro Munakata; Kazuhiro Nishikawa; Akinori Takagane; Takaho Tanaka; Yoshiaki Sekishita; Junichi Sakamoto; Akira Tsuburaya
    GASTRIC CANCER, Jul. 2012, [Reviewed]
  • Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
    Koji Kono; Hisae Iinuma; Yasunori Akutsu; Hiroaki Tanaka; Naoko Hayashi; Yasuto Uchikado; Tsuyoshi Noguchi; Hideki Fujii; Kota Okinaka; Ryoji Fukushima; Hisahiro Matsubara; Masaichi Ohira; Hideo Baba; Shoji Natsugoe; Seigou Kitano; Kazuyoshi Takeda; Koji Yoshida; Takuya Tsunoda; Yusuke Nakamura
    JOURNAL OF TRANSLATIONAL MEDICINE, Jul. 2012, [Reviewed]
  • Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer
    Taisuke Inoue; Hisae Iinuma; Etsushi Ogawa; Tsuyoshi Inaba; Ryoji Fukushima
    ONCOLOGY REPORTS, Jun. 2012, [Reviewed]
  • 栄養のKEY NOTE 経静脈栄養法 経静脈栄養法 合併症と対策               
    Jun. 2012, [Reviewed]
  • 【クリティカルケアに必要な糖代謝と栄養管理-SCCM/ASPEN栄養管理ガイドラインに準拠して-】 SCCM/ASPEN栄養管理ガイドライン 経静脈栄養の開始[SCCM/ASPEN栄養管理ガイドラインB1-3]               
    Jun. 2012, [Reviewed]
  • 【周術期の栄養管理ーERASプロトコールを巡って】 特集にあたって               
    May 2012, [Reviewed]
  • A Phase III Trial to Evaluate the Effect of Perioperative Nutrition Enriched with Eicosapentaenoic Acid on Body Weight Loss after Total Gastrectomy for T2T4a Gastric Cancer
    Takaki Yoshikawa; Naoki Hiki; Masataka Taguri; Takeshi Sano; Souya Nunobe; Hideki Taniguchi; Ryoji Fukushima; Haruhiko Cho; Satoshi Morita; Akira Tsuburaya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, May 2012, [Reviewed]
  • 【周術期の代謝栄養管理-ERASプロトコールを巡って】 ERASプロトコールの概要               
    May 2012, [Reviewed]
  • 【術前・術後管理必携】 術前検査 栄養評価               
    Apr. 2012, [Reviewed]
  • Usefulness of enhanced recovery after surgery protocol as compared with conventional perioperative care in gastric surgery
    Takanobu Yamada; Tsutomu Hayashi; Haruhiko Cho; Takaki Yoshikawa; Hideki Taniguchi; Ryoji Fukushima; Akira Tsuburaya
    GASTRIC CANCER, Jan. 2012, [Reviewed]
  • 進行胃癌治療の最前線 1.特集に寄せて               
    Jan. 2012, [Reviewed]
  • 【基本からわかる!栄養管理の実践】 【各論:こんなときどうする?】周術期の栄養管理               
    Dec. 2011, [Reviewed]
  • Stage4切除不能進行胃癌、腹膜播種に対してS-1/PTX静脈・腹腔内併用療法を行い根治手術可能になった1例 印象に残る症例               
    Aug. 2011
  • 【エビデンスと図解でさくさく理解! 手術部位感染対策をきわめる】 術前・術後の栄養療法               
    Aug. 2011, [Reviewed]
  • FUKUSHIMA NUCLEAR POWER PLANT ACCIDENT AND DISCLOSURE OF INFORMATION
    FUKUSHIMA Ryoji
    Journal of Japan Surgical Society, Jul. 2011, [Reviewed]
  • 【栄養管理を究める】 各論 胃全摘術後の栄養管理               
    Jul. 2011, [Reviewed]
  • 【術後食を再考する 新たなエビデンス構築に向けて】 術後食はいつ開始するべきか? 消化器外科術後の食事開始時期と形態について再考する               
    May 2011, [Reviewed]
  • 【栄養アセスメント 基礎から臨床へ】 免疫学的検査               
    May 2011, [Reviewed]
  • Vitamin C supplementation in patients receiving peripheral parenteral nutrition after gastrointestinal surgery
    Eriko Yamazaki; Masahiro Horikawa; Ryoji Fukushima
    NUTRITION, Apr. 2011, [Reviewed]
  • Clinical Significance of Circulating Tumor Cells, Including Cancer Stem-Like Cells, in Peripheral Blood for Recurrence and Prognosis in Patients With Dukes' Stage B and C Colorectal Cancer
    Hisae Iinuma; Toshiaki Watanabe; Koshi Mimori; Miki Adachi; Naoko Hayashi; Junko Tamura; Keiji Matsuda; Ryoji Fukushima; Kota Okinaga; Mitsuru Sasako; Masaki Mori
    JOURNAL OF CLINICAL ONCOLOGY, Apr. 2011, [Reviewed]
  • 【ERASに基づく術前・術中・術後管理】 合併症別 低栄養               
    Apr. 2011, [Reviewed]
  • 胃全摘後の空腸パウチ再建に関する検討               
    Mar. 2011
  • 「胃癌取り扱い規約」改訂が「がん登録制度」に及ぼした効果               
    Mar. 2011
  • Approach to Oral and Enteral Nutrition in Adults
    FUKUSHIMA Ryoji; SASAKI Masaya; OCKENGA Johann; NORMAN Kristina; OCKENGA Johann; NORMAN Kristina; VALENTINI Luzia; NORMAN Kristina
    Jomyaku Keicho Eiyo, Mar. 2011, [Reviewed]
  • Effect of Enteral Nutrition Formula Containing L-Isoleucine (DM-1) on Glycemic Control in Elderly Patients with Abnormal Glucose Tolerance
    FUKUSHIMA Ryoji; HASEBE Masaharu; MORITA Naomi; TANIGUCHI Masaaki; TAKADA Koji; MOTOMIYA Hiroshi; OIZUMI Akira; SHIKOSHI Akira; KANEKO Misato; TANAKA Yoshiaki
    Jomyaku Keicho Eiyo, Mar. 2011, [Reviewed]
    DM-1 is the new enteral nutrition formula supplemented with L-Isoleucine to inhibit hyperglycemia. In this study, we investigated this possibility for 20 elderly patients with abnormal glucose tolerance. Their fasting glucose levels were from 110 to 150 mg/dL and all of them were totally tube-fed. The patients were randomized to receive either DM-1 or a standard formula for the initial week and crossover to another formula for another week. Blood glucose and insulin concentrations were measured on the last day with either formula. The highest average blood glucose level in DM-1 group was significantly lower than that in the standard formula group (DM-1: 139±11mg/dL, standard formula: 148±12mg/dL). The average plasma insulin level in DM-1 group was also lower than that in the standard formula group. The results indicate that DM-1 has a potential to help with the glycemic control of elderly patients with abnormal glucose tolerance and tube feeding.
  • 胃瘻からの経管栄養投与速度に関する検討               
    Jan. 2011
  • Section 8 b) 若者における抗酸化物質の生物学的利用率の栄養状態による変化               
    Dec. 2010, [Reviewed]
  • Vitamin C requirement in surgical patients
    Ryoji Fukushima; Eriko Yamazaki
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, Nov. 2010, [Reviewed]
  • ESPENの周術期静脈栄養ガイドライン               
    Nov. 2010, [Reviewed]
  • 鼠径ヘルニアの術式・デバイスによる再発の特徴とその対策 Tension-free手術後再発鼠径ヘルニアの手術               
    Oct. 2010
  • 巨大小腸GIST摘出に対し術前に3DCT血管構築が支配血管の同定に有用であった1例               
    Oct. 2010
  • 当科における胃・十二指腸GIST症例に対する検討               
    Oct. 2010
  • Combination therapy using peptide vaccine and chemo-radiation therapy in esophageal cancer               
    Hisae Iinuma; Ryoji Fukushima; Junko Tamura; Taisuke Inoue; Masahiro Horikawa; Eriko Yamazaki; Kota Iwasaki; Tsuyoshi Inaba; Koji Yoshida; Takuya Tsunoda; Yusuke Nakamura; Kota Okinaga
    Biotherapy, Sep. 2010
  • がんペプチドワクチン療法 食道癌に対する化学放射線療法と新規ペプチドワクチン併用療法               
    Sep. 2010
  • 胃癌におけるcancer stem cellマーカーの同定と腹膜再発早期診断への臨床応用               
    Sep. 2010
  • 胃原発のMyxoid epithelioid GISTの一例               
    Sep. 2010, [Reviewed]
  • 【固形癌に対するペプチドワクチンの臨床応用】 食道がんにおける放射線化学療法併用免疫療法の意義               
    Sep. 2010, [Reviewed]
  • 消化器癌に対する新たな免疫療法の臨床応用 切除不能進行・再発食道癌に対する化学放射線とペプチドワクチン併用療法の第I相臨床試験               
    Jul. 2010
  • 多量の腹水を有す胃癌腹膜播種に対するPaclitaxel腹腔内投与症例の検討               
    Jul. 2010
  • 【インクレチン製剤 基礎と臨床】 外科手術とインクレチンの関係は? 胃や小腸を切除すると、インクレチンはどうなりますか               
    Jul. 2010, [Reviewed]
  • 【研修医必読 外科感染症のup to date】 感染症対策としての栄養管理               
    Jun. 2010, [Reviewed]
  • 【輸液・栄養管理 病態に応じた質と量】 各種輸液製剤の投与法 アミノ酸輸液の投与法               
    Jun. 2010, [Reviewed]
  • 【輸液・栄養管理 病態に応じた質と量】 消化器外科における輸液・栄養管理の実際 消化管手術               
    Jun. 2010, [Reviewed]
  • 【ワンステップアップ経腸栄養】 上級コース 経腸栄養のスペシャリストになろう!外科疾患(周術期)における経腸栄養剤の使い方と選び方               
    Jun. 2010, [Reviewed]
  • ヘルニア修復における術式の選択 腹壁ヘルニアの術式選択 どういう患者にどの術式を勧めるべきなのか               
    May 2010
  • 用語解説 アルギニン               
    May 2010, [Reviewed]
  • 【マスターしておきたい縫合・吻合法の実際 より安全・確実に行うために】 縫合・吻合法の実際 胃瘻・空腸瘻               
    Apr. 2010, [Reviewed]
  • 【外科当直医必携】 救急外来当直医必携 症状別の初療と診断のすすめ方 食欲不振               
    Apr. 2010, [Reviewed]
  • 腹膜播種を有する胃癌症例を対象とした腹腔内ポート留置の検討               
    Mar. 2010
  • 高齢者胃癌治療の現状と問題点               
    Mar. 2010
  • 【静脈・経腸栄養(第3版) 基礎・臨床研究のアップデート】 各種疾患、病態における静脈・経腸栄養の実際 嘔吐、下痢、脱水症               
    Mar. 2010, [Reviewed]
  • 【静脈・経腸栄養(第3版) 基礎・臨床研究のアップデート】 Immunonutrition(免疫栄養法) 栄養管理における位置づけ               
    Mar. 2010, [Reviewed]
  • 【静脈・経腸栄養(第3版) 基礎・臨床研究のアップデート】 Immunonutrition(免疫栄養法) 臨床への展開               
    Mar. 2010, [Reviewed]
  • 胃癌術後早期に門脈ガス血症を伴う腸管気腫症を認めた一例               
    Feb. 2010
  • 【多剤耐性菌感染症】 Multidrug-resistant Pseudomonas aeruginosa(MDRP)感染症               
    Feb. 2010, [Reviewed]
  • 胃瘻 長期管理における問題点と対策 超細径内視鏡を用いた胃瘻交換時の確認               
    Jan. 2010
  • 間接熱量から考える上部消化管周術期の栄養管理               
    Jan. 2010
  • 【消化器外科術後食に関する新しい考え方】 鏡視下手術がもたらしたもの 胃切除術               
    Jan. 2010, [Reviewed]
  • 【必読 一冊に凝縮した研修医のための手術書】 各論 ヘルニア 鼠径・大腿ヘルニア 再発鼠径ヘルニアの手術               
    Nov. 2009, [Reviewed]
  • 腹壁瘢痕ヘルニアの治療 大学病院における腹壁瘢痕ヘルニア手術の現状と問題点               
    Oct. 2009
  • 胃癌術後早期に腸管気腫、門脈ガスを伴った2症例               
    Oct. 2009
  • 鼠径ヘルニア術後血腫にて治療に難渋した一例               
    Oct. 2009
  • 胃癌におけるCD133・CEA・CK20mRNAを指標とした腹膜再発の早期遺伝子診断と治療戦略               
    Sep. 2009
  • 巻頭言 必要エネルギー量の算出法と投与の実際               
    Sep. 2009, [Reviewed]
  • 【外科基本手技アトラス】 外科基本手技・処置 血管ルートの取り方               
    Sep. 2009, [Reviewed]
  • 【胃切除後の諸問題】 胃切除後障害 ダンピング症候群の病態と治療               
    Sep. 2009, [Reviewed]
  • ソケイヘルニアの分類規約・ガイドラインを考える 学会ヘルニア分類改定試案によって分類がどう変わるのか               
    Aug. 2009
  • 両側Spigelヘルニアの一例               
    Aug. 2009
  • 【新・静脈栄養・経腸栄養ガイド NSTに必須の知識と実践のすべて】 周術期の栄養管理の実際 胃手術               
    Jul. 2009, [Reviewed]
  • 特集にあたって               
    Jun. 2009, [Reviewed]
  • Bacterial translocation 周術期におけるBacteria translocationの意義               
    May 2009
  • ヘルニア手術の進歩 日本ヘルニア学会の鼠径部ヘルニア分類は術式決定に有用か               
    May 2009
  • 胃切除後のドレーン留置の現状               
    May 2009
  • 特異な形態をとった鼠径ヘルニアの3例               
    May 2009
  • 胃癌患者における血中CA-125測定の意義               
    Mar. 2009
  • Efficient CTL productivity of modified fusion cells by increase of heat shock protein 70
    Taihei Koide; Hisae Iinuma; Ryoji Fukushima
    ONCOLOGY REPORTS, Mar. 2009, [Reviewed]
  • グルタミン投与にて短期間に軽快した、再発単純性潰瘍の一例               
    Jan. 2009
  • Nutrition Day 日本からの参加意義と今後の課題               
    Jan. 2009
  • 周術期の静脈経腸栄養に関するESPENガイドライン(監訳)               
    2009, [Reviewed]
  • 【知っておきたい外科栄養管理とNST】 外科医に必要な栄養アセスメントの知識               
    Jan. 2009, [Reviewed]
  • 【変わりつつある周術期感染予防と治療 SSIを中心に】 感染予防のための周術期管理 手術をする前にやっておくこと 術前管理の要点               
    Jan. 2009, [Reviewed]
  • 細胞融合とプロテオーム解析を用いた癌治療の新たな標的分子の探索               
    Dec. 2008, [Reviewed]
  • 【生体侵襲と臓器管理 急性期病態の理解とその対応】 生体侵襲 Bacterial Translocationによる生体侵襲               
    Nov. 2008, [Reviewed]
  • 教育病院の手洗いも簡素化してよいのか?               
    Oct. 2008
  • 再発鼠径ヘルニアの現状と対策               
    Oct. 2008
  • 当科で行った胃癌に対する膵頭十二指腸切除術の検討               
    Oct. 2008
  • 【NST病態栄養シリーズ Immunonutrition】 腸管のバリア機能と早期経腸栄養               
    Aug. 2008, [Reviewed]
  • 周術期におけるエネルギー・基質代謝の変化と栄養投与               
    Aug. 2008, [Reviewed]
  • Identification of novel molecular target by utilizing proteome analysis of fusion cells               
    Hisae Iinuma; Ryoji Fukushima; Kota Okinaga
    Biotherapy, Jul. 2008
  • 【次世代バイオセラピィの分子標的】 細胞融合とプロテオーム解析による新規標的分子の探索               
    Jul. 2008, [Reviewed]
  • 【栄養サポートのアウトカム評価】 栄養サポートの免疫能に及ぼす効果と外科的アウトカム               
    Jun. 2008, [Reviewed]
  • 手術前夜の禁飲食はもう古い?? 術前の飲水、糖水投与のエビデンス               
    Mar. 2008, [Reviewed]
  • 【栄養療法 臨床栄養の新しい潮流】 栄養に関する新しい概念 免疫栄養法               
    Mar. 2008, [Reviewed]
  • 周術期における血液凝固第XIII因子製剤フィブロガミンPの可能性               
    Mar. 2008, [Reviewed]
  • 【全科に必要な栄養管理Q&A 初歩的な知識からNSTの実際まで】 栄養アセスメント 栄養に関する免疫学的指標は?               
    Feb. 2008, [Reviewed]
  • 特集 救急外来で慌てない!急性腹症の診断と治療の基本               
    2008, [Reviewed]
  • 長期生存が得られている膵原発悪性内分泌腫瘍の一例               
    Nov. 2007
  • 中学生以上成人未満の外鼠径ヘルニアの治療 当科における12歳以上20歳未満の鼠径ヘルニア症例の検討               
    Nov. 2007
  • 胃癌に対する色素法Sentinel Navigation Surgeryの問題点               
    Nov. 2007
  • 早期胃癌術後の十二指腸転移の一例               
    Nov. 2007
  • 胃癌術後の舌転移の1例               
    Sep. 2007
  • 高度進行食道癌をどう治療するべきなのか               
    Sep. 2007
  • 【救急医療領域における感染症】 敗血症 Immune-enhancing nutrition               
    Sep. 2007, [Reviewed]
  • 【Surgical Site Infection(SSI)対策】 新しいSSI対策 術中の体温管理               
    Aug. 2007, [Reviewed]
  • Bacterial translocationの対策 栄養管理を中心に               
    Jul. 2007, [Reviewed]
  • The results of a national survey for TNT attendants about the present status of clinical nutrition in Japan
    INOUE Yoshifumi; IKEDA Kenichiro; OMURA Kenji; TABIRA Yoichi; FUKUSHIMA Ryoji; OHYANAGI Harumasa
    Jomyaku Keicho Eiyo, Jun. 2007, [Reviewed]
  • The results of a national survey for TNT attendants about the present status of clinical nutrition in Japan
    INOUE Yoshifumi; IKEDA Kenichiro; OMURA Kenji; TABIRA Yoichi; FUKUSHIMA Ryoji; OHYANAGI Harumasa
    Jomyaku Keicho Eiyo, Jun. 2007, [Reviewed]
  • 【QOL重視の消化器術前・術後栄養管理 内視鏡手術を中心に】 術後の早期経腸栄養の意義               
    May 2007, [Reviewed]
  • 【手術室の最新情報】 術前の腸管プレパレーション               
    Mar. 2007, [Reviewed]
  • イレウス 胃全摘Roux-Y再建後のY脚部に腸閉塞を来した2症例               
    Feb. 2007
  • 【研修医が身につけたい外科周術期管理の基本】 術後患者の管理               
    Dec. 2006, [Reviewed]
  • ナースが取り組む 栄養療法 実践編 待期手術患者に対するImmunonutrition(免疫賦活栄養法)               
    Nov. 2006, [Reviewed]
  • 胃全摘Roux-Y再建術の17年後に空腸空腸吻合の閉塞を来した1例               
    Oct. 2006
  • 【術前・術後Q&A 新しくなったケアの根拠】 感染症やその他の合併症対策               
    Oct. 2006, [Reviewed]
  • 【日常における耐性菌制御 アウトブレイクを未然に防ぐために】 耐性菌を出さないための抗菌薬使用ストラテジー 抗菌薬サイクリング/ミキシング               
    Oct. 2006, [Reviewed]
  • Effect of immunotherapy and immunological function in patients spleen preservation on with gastric cancer
    K. Okinaga; H. Iinuma; Y. Kitamura; T. Yokohata; T. Inaba; R. Fukushima
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, Sep. 2006, [Reviewed]
  • 【これからの術後感染の対策・治療を考える】 術後感染治療薬 Antibiotic heterogeneity               
    Sep. 2006, [Reviewed]
  • 【術後遠隔期の栄養障害と対策】 胃全摘術後               
    Aug. 2006, [Reviewed]
  • 【新しい外科栄養管理 Immunonutrition】 Immunonutritionの概要 Immunonutritionとは               
    Apr. 2006, [Reviewed]
  • 【消化器疾患 State of arts 消化管(食道・胃・腸)】 治療法をめぐる最近の進歩 栄養管理 経腸栄養の進歩               
    Apr. 2006, [Reviewed]
  • Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma
    Hisae Iinuma; Kota Okinaga; Ryoji Fukushima; Tsuyoshi Inaba; Kota Iwasaki; Akira Okinaga; Ichiro Takahashi; Michio Kaneko
    JOURNAL OF IMMUNOLOGY, Mar. 2006, [Reviewed]
  • 【癌免疫療法の効果判定法について】 癌免疫療法における免疫モニタリングの可能性               
    Mar. 2006, [Reviewed]
  • 【消化管術後食の常識を見直す】 術後食の段階的食事アップは必要か 上部消化管               
    Feb. 2006, [Reviewed]
  • 輸液栄養管理とリスクマネジメント ビタミンB1欠乏と輸液管理               
    2006, [Reviewed]
  • 【アッペ・ヘモ・ヘルニア・下肢バリックスの手術】 ヘルニア 従来法によるヘルニア修復術               
    Nov. 2005, [Reviewed]
  • 【ストレスと疾患・栄養】 ストレスと胃腸障害               
    Nov. 2005, [Reviewed]
  • [Fusion vaccine therapy by IL-2-gene-transduced dendritic cells and tumor cells].
    Ogawa F; Iinuma H; Iwasaki K; Tamura J; Kumagai H; Inaba T; Fukushima R; Kota O
    Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2005, [Reviewed]
  • マウスにおける脾臓由来のIL-2遺伝子導入樹状細胞と癌細胞の融合細胞によるワクチン療法               
    Oct. 2005, [Reviewed]
  • 【再手術 予防・適応・手術手技】 鼠径・大腿ヘルニア再発               
    Sep. 2005, [Reviewed]
  • 【全科に必要な栄養管理Q&A 初歩的な知識からNSTの実際まで】 栄養アセスメント 栄養に関する免疫学的指標は?               
    Sep. 2005, [Reviewed]
  • 【臓器別・トラブル別にわかる!栄養管理&食事指導のポイント】 immunonutritionとは?               
    Aug. 2005, [Reviewed]
  • 【看護に活かす臨床栄養管理】 臨床栄養のトピックス Immunonutrition(免疫賦活栄養法)               
    Apr. 2005, [Reviewed]
  • PEGの適応と栄養管理               
    Mar. 2005, [Reviewed]
  • 【Immunonutritionの新展開】 Immunonutritionの経済効果               
    Mar. 2005, [Reviewed]
  • Immunonutrition 術後感染予防やsepsis治療における適応の是非               
    Mar. 2005, [Reviewed]
  • Is jejunal pouch reconstruction useful after total gastrectomy?
    R Fukushima; T Koide; H Yamada; K Iwasaki; H Iinuma; Y Ikeda; T Inaba; K Okinaga
    Proceedings of the 6th International Gastric Cancer Congress, 2005, [Reviewed]
  • Comparison of jejunal pouch interposition and jejunal loop interposition as reconstruction method after proximal gastrectomy
    T Inaba; R Fukushima; Y Ikeda; K Iwasaki; H Yamada; K Okinaga
    Proceedings of the 6th International Gastric Cancer Congress, 2005, [Reviewed]
  • わが病院の感染対策 帝京大学医学部附属病院における院内感染対策               
    Jan. 2005, [Reviewed]
  • 栄養療法の実施状況に関する全国アンケート調査結果報告(4)               
    Dec. 2004, [Reviewed]
  • [Perioperative nosocomial infection preventive measures].
    Fukushima R; Inaba T; Iinuma H; Okinaga K
    Nihon Geka Gakkai zasshi, Nov. 2004, [Reviewed]
  • 【周術期の院内感染対策】 宿主対策               
    Nov. 2004, [Reviewed]
  • [Reduction of immunosuppression and shift to Th1 response by tumor-DC (dendritic cells) fusion vaccine].
    Iinuma H; Okinaga K; Fukushima R; Inaba T; Iwasaki K; Arai T; Tamura J; Kumagai H
    Gan to kagaku ryoho. Cancer & chemotherapy, Oct. 2004, [Reviewed]
  • 樹状細胞と腫瘍の融合細胞ワクチン投与による免疫抑制解除とTh1系へのシフト               
    Oct. 2004, [Reviewed]
  • 栄養療法の実施状況に関する全国アンケート調査結果報告(3)               
    Sep. 2004, [Reviewed]
  • 【栄養管理を極める! 症例とQ&Aで学ぶ】 広範囲熱傷               
    Aug. 2004, [Reviewed]
  • 栄養療法の実施状況に関する全国アンケート調査結果報告(2)               
    Jun. 2004, [Reviewed]
  • 【術後の経過がこんなに変わる!根拠に基づく新しい術後ケア】 血糖コントロールは術後48時間までが勝負               
    May 2004, [Reviewed]
  • 【胃癌治療 update 2004】 胃癌の治療 合併症の治療 胃癌穿孔の治療               
    May 2004, [Reviewed]
  • 栄養療法の実施状況に関する全国アンケート調査結果報告(1)               
    Mar. 2004, [Reviewed]
  • 急性腹症の超音波診断 消化管穿孔,穿孔性腹膜炎の超音波診断               
    Feb. 2004, [Reviewed]
  • 【外科領域における栄養管理】 本邦における栄養管理の現状 2001年全国栄養療法アンケート調査より               
    Feb. 2004, [Reviewed]
  • 樹状細胞と肝移植               
    2004, [Reviewed]
  • Prospective randomized study of two laparotomy incisions for gastrectomy: Midline incision versus transverse incision
    Tsuyoshi Inaba; Kota Okinaga; Ryoji Fukushima; Hisae Iinuma; Takashi Ogihara; Fujio Ogawa; Kota Iwasaki; Masanao Tanaka; Hideki Yamada
    Gastric Cancer, 2004, [Reviewed]
  • TOPICS 消化器外科学 消化器外科手術における予防的抗菌薬投与期間に関する検討               
    Dec. 2003, [Reviewed]
  • Simultaneous onset of acute inflammatory response, sepsis-like symptoms and intestinal mucosal injury after cancer chemotherapy
    E Tsuji; N Hiki; S Nomura; R Fukushima; J Kojima; T Ogawa; K Mafune; Y Mimura; M Kaminishi
    INTERNATIONAL JOURNAL OF CANCER, Nov. 2003, [Reviewed]
  • 日常診療の指針 術後栄養状態,愁訴,胃排出能からみた幽門保存胃切除術の意義               
    Nov. 2003, [Reviewed]
  • 【Abdominal critical care】 治療法総論 経腸栄養(EN)によるimmunomodulation               
    Oct. 2003, [Reviewed]
  • 【アミノ酸の生理機能 新しい展開】 アルギニンの免疫賦活機能 基礎的研究から               
    Oct. 2003, [Reviewed]
  • 術後感染防止をめざした外科手術手技 胃癌手術後の術後感染性合併症発生は切開法によって異なるのか               
    Oct. 2003, [Reviewed]
  • 食道癌術後にムーコル創感染を併発し重症化した症例               
    Oct. 2003, [Reviewed]
  • [Molecular diagnosis of infectious disease].
    Fukushima R; Kawakami S; Iinuma H; Okinaga K
    Nihon Geka Gakkai zasshi, Jul. 2003, [Reviewed]
  • 【感染症と分子生物学】 感染症診断における分子生物学の応用               
    Jul. 2003, [Reviewed]
  • 急性炎症モデル作製法               
    Jun. 2003, [Reviewed]
  • 【イレウス 診断と治療の進歩】 イレウスの原因とその病態               
    Jun. 2003, [Reviewed]
  • 【ベッドサイド処置アトラス】 救急蘇生とインテンシブ・ケアに必要な処置 輪状甲状靱帯穿刺               
    May 2003, [Reviewed]
  • 【消化器外科とクリニカルパス】 鼠径ヘルニア手術のクリニカルパス               
    Apr. 2003, [Reviewed]
  • Bacterial Translocation and Immunonutrition
    FUKUSHIMA Ryoji; KOBAYASHI Satoshi; INABA Tsuyoshi; IINUMA Hisae; OKINAGA Kota; SAITO Hideaki
    Progress in Acute Abdominal Medicine, Mar. 2003, [Reviewed]
    The use of enteral feeding enriched with immuneenhancing ingredients as well as the administration of certain growth factors in patients with stress have recently attracted considerable interest. These approaches to modulating the immune and inflammatory responses and thereby improving the clinical outcome are collectively known as immunonutrition. Prospective randomized clinical trails performed in the US and Europe have shown that early enteral feeding enriched with glutamine, arginine, omega-3 fatty acids and nucleotides significantly reduces infectious complications and the length of the hospital stay. Most immunonutrition strategies have been shown to modulate gut function, i.e. to prevent bacterial translocation, in animal models. Whether bacterial translocation is an important pathophysiological event in human disease or an epiphenomenon of severe disease remains debatable, but maintenance of gut barrier function may explain, at least in part, the clinical benefits of immunonutrition.
  • 【エネルギー投与量をみなおす】 外科手術患者の周術期エネルギー投与量               
    Mar. 2003, [Reviewed]
  • 消化器外科術後末梢静脈栄養(PPN)施行時にビタミンB1投与は必要か 術前術後のビタミンB1血中濃度の推移からみた検討               
    Feb. 2003, [Reviewed]
  • 【最良の癌手術とは?】 手術侵襲をどのように評価するか               
    Dec. 2002, [Reviewed]
  • 【外科侵襲期に有用な栄養基質】 侵襲期における分岐鎖アミノ酸投与の栄養状態改善効果について その問題点と意義について               
    Dec. 2002, [Reviewed]
  • 【Immunonutrition】 Immunonutritionのmeta-analysis               
    Dec. 2002, [Reviewed]
  • 大腸手術における術前腸管処置 経口抗菌薬投与の有無と腸内細菌株の変化を中心に               
    Sep. 2002, [Reviewed]
  • Functional results after pylorus-preserving gastrectomy
    K Okinaga; T Ogiwara; R Fukushima; T Inaba; F Ogawa; M Shiratori; H Yago; H Iinuma
    XXXIII WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS - ICS 2002, 2002, [Reviewed]
  • Alanyl-glutamine enriched total parenteral nutrition improves local, systemic, and remote organ responses to intraperitoneal bacterial challenge
    MT Lin; H Saito; S Furukawa; R Fukushima; F Kazuhiko; PH Lee; KJ Chang; WJ Chen
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, Nov. 2001, [Reviewed]
  • 【腹部損傷に対する手術 臓器温存・QOLの視点から】 脾損傷の手術               
    Sep. 2001, [Reviewed]
  • 【NSTの立ちあげと運営】 NSTにおける医師の役割               
    Aug. 2001, [Reviewed]
  • 【疾患別静脈・経腸栄養の実際】 熱傷               
    Jun. 2001, [Reviewed]
  • 消化管の憩室               
    Jun. 2001, [Reviewed]
  • 【静脈・経腸栄養】 各種疾患における静脈・経腸栄養の実際 嘔吐,下痢,脱水症における静脈・経腸栄養               
    May 2001, [Reviewed]
  • 【消化器疾患の分子医学】 消化器疾患の臨床と分子医学の接点 活性酸素とNO 微小循環でのストレス応答               
    May 2001, [Reviewed]
  • 【静脈・経腸栄養】 欧米における新経腸栄養製剤               
    May 2001, [Reviewed]
  • 【特殊病態併存患者の周術期管理】 低栄養患者の周術期管理               
    May 2001, [Reviewed]
  • 【重症感染症をどう制御するか? 新しい管理法と治療戦略】 救急・集中治療におけるnosocomial infectionとその対策 Bacterial TranslocationとSDD               
    Mar. 2001, [Reviewed]
  • 【Pharmacological nutrition, Immunonutrition】 成長因子(特にIGF-I)               
    Feb. 2001, [Reviewed]
  • 【Pharmacological nutrition, Immunonutrition】 immunonutritionとしての栄養投与ルート               
    Feb. 2001, [Reviewed]
  • 内視鏡的胃瘻造設術の検討               
    Jan. 2001
  • 消化器外科周術期の適切な抗菌薬使用期間の検討               
    2001, [Reviewed]
  • 臨床医学の展望 代謝と栄養               
    2001, [Reviewed]
  • 【外科感染症 21世紀における新たな挑戦】 21世紀の外科感染症対策の展望               
    Dec. 2000, [Reviewed]
  • 臨床医のためのわかりやすい基礎科学 消化器外科とimmunonutrition               
    Nov. 2000, [Reviewed]
  • シリーズ・消化管疾患の薬物療法 消化管手術後の異常の薬物療法               
    Oct. 2000, [Reviewed]
  • 待期的な消化器外科手術症例における術後予防的抗菌薬投与期間に関するprospective randomized study               
    Jul. 2000, [Reviewed]
  • 【手術に使用する器械マニュアル】 開腹手術編 チューブ               
    Apr. 2000, [Reviewed]
  • Assessment of Th1/Th2 balance for monitoring of OK-432 immunotherapy               
    H. Iinuma; K. Okinaga; J. Tamura; H. Kumagai; T. Sekine; T. Inaba; R. Fukushima
    Biotherapy, 2000
  • マンソン住血吸虫による直腸炎の一例               
    2000, [Reviewed]
  • OK-432治療効果のTh1/Th2バランスによる評価               
    2000, [Reviewed]
  • 臨床医学の展望 代謝と栄養               
    2000, [Reviewed]
  • 臨床医学の展望 侵襲と生体反応               
    2000, [Reviewed]
  • 【炎症性腸疾患の合併症と緊急手術の適応】 Behcet病に対する外科手術               
    Jan. 2000, [Reviewed]
  • 【免疫臓器としての腸】 腸粘膜免疫とbacterial translocation               
    Dec. 1999, [Reviewed]
  • 【栄養アセスメント 各種栄養アセスメントの特徴とその評価法の限界について】 血液生化学によるアセスメント               
    Dec. 1999, [Reviewed]
  • 【栄養管理からみたbacterial translocation】 栄養管理からみたbacterial translocation 開腹手術と術後早期経腸栄養について               
    Nov. 1999, [Reviewed]
  • 80歳以上高齢者胃癌の検討               
    Oct. 1999, [Reviewed]
  • 【消化器疾患とNO】 NOの生体作用を修飾する諸因子(hormone,cytokine,oxygen free radicalなど)               
    May 1999, [Reviewed]
  • 【腹部救急診療最前線】 高齢者におけるピットフォールとその対策               
    May 1999, [Reviewed]
  • 【ベッドサイド・ハンドブック】 入院における全身管理 輸液と栄養管理               
    May 1999, [Reviewed]
  • 臨床医学の展望 代謝と栄養               
    1999, [Reviewed]
  • 臨床医学の展望 侵襲と生体反応               
    1999, [Reviewed]
  • 【侵襲学の基礎を学ぶ】 侵襲と生体反応の軽減 Gut decontamination               
    Dec. 1998, [Reviewed]
  • 術後予防的抗菌薬短期投与に関する検討               
    Nov. 1998, [Reviewed]
  • Reperfusion induces sublethal endothelial injury
    K Nishida; Y Miyazawa; M Hatano; K Suzuki; A Hirose; R Fukushima; K Okinaga
    JOURNAL OF SURGICAL RESEARCH, Sep. 1998, [Reviewed]
  • 【臓器不全の病態と対策】 Bacterial translocation(BT)と臓器不全               
    Aug. 1998, [Reviewed]
  • Bacterial Translocationの予防と治療               
    Aug. 1998, [Reviewed]
  • 免疫化学療法を併用した膵脾温存胃全摘術の検討               
    May 1998, [Reviewed]
  • 【感染症と栄養をめぐる諸問題】 bacterial translocationをめぐる諸問題               
    May 1998, [Reviewed]
  • 【経静脈・経腸栄養療法のストラテジー】 栄養不良症の成因と疾病治療における重要性 入院患者での蛋白栄養不良症の頻度とその成因               
    Feb. 1998, [Reviewed]
  • 【輸液療法UPDATE】 TPN-UPDATE TPNの問題点 Bacterial translocation               
    Nov. 1997, [Reviewed]
  • 【周術期感染症の予防と治療】 予防的抗菌薬投与法の再検討               
    Nov. 1997, [Reviewed]
  • 体温の臨床 SIRSと体温               
    Sep. 1997, [Reviewed]
  • 外科当直医を始める人のために 細菌性ショックの処置               
    Sep. 1997, [Reviewed]
  • 臨床外科医のためのSIRS SIRSの病態とそのメディエータ               
    Jun. 1997, [Reviewed]
  • Insulin-like growth factor 1 has beneficial effects, whereas growth hormone has limited effects on postoperative protein metabolism, gut integrity, and splenic weight in rats with chronic mild liver injury
    T Inaba; H Saito; R Fukushima; Y Hashiguchi; MT Lin; T Inoue; K Fukatsu; T Muto; T Oka; A Takenaka; SI Takahashi; T Noguchi
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, Mar. 1997, [Reviewed]
  • Alanylglutamine-enriched total parenteral nutrition improves protein metabolism more than branched chain amino acid-enriched total parenteral nutrition in protracted peritonitis
    S Naka; H Saito; Y Hashiguchi; MT Lin; S Furukawa; T Inaba; R Fukushima; N Wada; T Muto
    JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, Feb. 1997, [Reviewed]
  • Interleukin-1 and tumor necrosis factor alter plasma concentration and interorgan fluxes of taurine in dogs
    Y Hashiguchi; R Fukushima; H Saito; S Naka; T Inaba; MT Lin; T Muto
    SHOCK, Feb. 1997, [Reviewed]
  • Alanylglutamine-enriched total parenteral nutrition improves protein metabolism more than branched chain amino acid-enriched total parenteral nutrition in protracted peritonitis.
    Naka S; Saito H; Hashiguchi Y; Lin MT; Furukawa S; Inaba T; Fukushima R; Wada N; Muto T
    The Journal of trauma, Feb. 1997, [Reviewed]
  • Preoperative total parenteral nutrition influences postoperative systemic cytokine responses after colorectal surgery
    MT Lin; H Saito; R Fukushima; T Inaba; K Fukatsu; T Inoue; S Furukawa; Han, I; T Matsuda; T Muto
    NUTRITION, Jan. 1997, [Reviewed]
  • 腹膜炎モデルでのアラニルグルタミン添加TPNによる脾臓Interferon-γ産生の増強               
    Jan. 1997, [Reviewed]
  • 消化管とMOF 実験によるbacterial translocationとMOF               
    Jan. 1997, [Reviewed]
  • Effects of growth hormone and insulin-like growth factor 1 (IGF-1) on hepatic IGF-1-mRNA, plasma IGF-1 and nitrogen excretion in gastrectomized rats with liver cirrhosis
    T Inaba; H Saito; R Fukushima; Y Hashiguchi; MT Lin; T Inoue; K Fukatsu; T Muto; T Oka; A Takenaka; S Takahashi; T Noguchi
    CLINICAL NUTRITION, Dec. 1996, [Reviewed]
  • 侵襲期栄養管理の新展開 栄養投与ルートと生体反応               
    Dec. 1996, [Reviewed]
  • Alanyl-glutamine-supplemented total parenteral nutrition improves survival and protein metabolism in rat protracted bacterial peritonitis model
    S Naka; H Saito; Y Hashiguchi; MT Lin; S Furukawa; T Inaba; R Fukushima; N Wada; T Muto
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, Nov. 1996, [Reviewed]
  • 癒着性イレウスの診断と治療 Mucosal barrierとbacterial translocation               
    Nov. 1996, [Reviewed]
  • Interleukin-6 and stress hormone responses after uncomplicated gasless laparoscopic-assisted and open sigmoid colectomy
    R Fukushima; YJ Kawamura; H Saito; Y Saito; Y Hashiguchi; T Sawada; T Muto
    DISEASES OF THE COLON & RECTUM, Oct. 1996, [Reviewed]
  • Effects of growth hormone and insulin-like growth factor 1 (IGF-1) treatments on the nitrogen metabolism and hepatic IGF-1-messenger RNA expression in postoperative parenterally fed rats
    T Inaba; H Saito; R Fukushima; Y Hashiguchi; MT Lin; T Inoue; K Fukatsu; T Muto; A Takenaka; S Takahashi; T Noguchi
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, Sep. 1996, [Reviewed]
  • 救急領域の病態とSIRS Bacterial translocationとSIRS               
    Sep. 1996, [Reviewed]
  • 併存疾患の術前術後管理 低栄養と貧血               
    Aug. 1996, [Reviewed]
  • Steroid therapy can modulate gut barrier function, host defense, and survival in thermally injured mice
    L Gianotti; JW Alexander; R Fukushima; T Pyles
    JOURNAL OF SURGICAL RESEARCH, Apr. 1996, [Reviewed]
  • 栄養と免疫 外科系領域における生体防御能を高める栄養法               
    Apr. 1996, [Reviewed]
  • Effects of three inhibitors of nitric oxide synthase on host resistance to bacterial infection
    K Fukatsu; H Saito; R Fukushima; MT Lin; T Inoue; T Inaba; S Furukawa; L Han; T Muto
    INFLAMMATION RESEARCH, Mar. 1996, [Reviewed]
  • Response to OK-432 in immunochemotherapy for patients with gastric cancer               
    H. Iinuma; K. Okinaga; J. Tamura; H. Kumagai; T. Yokohata; R. Fukushima
    Biotherapy, 1996
  • Detection of p53 tumor suppressor gene mutation in advanced gastric carcinoma is not independently prognostic
    T Fuke; H Iinuma; R Fukushima; K Okinaga
    XXX WORLD CONGRESS OF THE INTERNATIONAL COLLEGE OF SURGEONS, VOLS 1-2, 1996, [Reviewed]
  • Growth hormone improves survival in a murine model of gram-negative sepsis
    T Inoue; H Saito; R Fukushima; K Fukatsu; MT Lin; T Inaba; T Muto
    IMMUNE CONSEQUENCES OF TRAUMA, SHOCK AND SEPSIS - MECHANISMS AND THERAPEUTIC APPROACHES, VOL II, PTS 1 AND 2, 1996, [Reviewed]
  • Inhibition of nitric oxide synthase is detrimental in a mouse model of sepsis
    K Fukatsu; H Saito; R Fukushima; T Inoue; MT Lin; T Inaba; T Muto
    IMMUNE CONSEQUENCES OF TRAUMA, SHOCK AND SEPSIS - MECHANISMS AND THERAPEUTIC APPROACHES, VOL I, 1996, [Reviewed]
  • Parenteral vs enteral nutrition: Different host responses to infection
    MT Lin; H Saito; R Fukushima; T Inaba; T Inoue; K Fukatsu; T Muto
    IMMUNE CONSEQUENCES OF TRAUMA, SHOCK AND SEPSIS - MECHANISMS AND THERAPEUTIC APPROACHES, VOL II, PTS 1 AND 2, 1996, [Reviewed]
  • 胃癌治癒切除例の免疫化学療法におけるOK-432の応答性               
    1996, [Reviewed]
  • Autologous blood transfusion in gastro-intestinal cancer operation - The usefulness of recombinant human erythropoietin (r-HuEPO) in preoperative blood donation
    Masahisa Kato; Nobuhiro Wakimoto; Kiki Adachi; Tokuyuki Yokohata; Ryoji Fukushima; Mitsuaki Anzai; Kazuko Sakae; Miyuki Sugiyama; Kota Okinaga
    Japanese Journal of Gastroenterological Surgery, 1996, [Reviewed]
  • Route of nutritional supply influences local, systemic, and remote organ responses to intraperitoneal bacterial challenge
    MT Lin; H Saito; R Fukushima; T Inaba; K Fukatsu; T Inoue; S Furukawa; Han, I; T Muto
    ANNALS OF SURGERY, Jan. 1996, [Reviewed]
  • Growth hormone and the immune response to bacterial infection
    H Saito; T Inoue; K Fukatsu; L MingTsan; T Inaba; R Fukushima; T Muto
    HORMONE RESEARCH, 1996, [Reviewed]
  • 栄養投与ルート:経静脈vs経腸栄養               
    1996, [Reviewed]
  • TNF産生におけるENとTPNの比較               
    1996, [Reviewed]
  • 静注用アミノ酸製剤の問題点 タウリン、シスチン、チロシン               
    1996, [Reviewed]
  • Bacterial translocation               
    1996, [Reviewed]
  • 感染症集中治療中の栄養管理               
    Jan. 1996, [Reviewed]
  • 腹膜の炎症とサイトカイン               
    Nov. 1995, [Reviewed]
  • HORMONE AND INSULIN-LIKE GROWTH-FACTOR-I ENHANCE HOST-DEFENSE IN A MURINE SEPSIS MODEL
    L INOUE; H SAITO; R FUKUSHIMA; T INABA; MT LIN; K FUKATSU; T MUTO
    ARCHIVES OF SURGERY, Oct. 1995, [Reviewed]
  • 腸粘膜萎縮の病態とその対策 腸粘膜萎縮にともなう機能的変化 免疫の面から               
    Jun. 1995, [Reviewed]
  • BACTERIAL TRANSLOCATION-RELATED MORTALITY MAY BE ASSOCIATED WITH NEUTROPHIL-MEDIATED ORGAN DAMAGE
    R FUKUSHIMA; JW ALEXANDER; L GIANOTTI; T PYLES; CK OGLE
    SHOCK, May 1995, [Reviewed]
  • 手術侵襲・外傷 Immunonutrition               
    May 1995, [Reviewed]
  • Bacterial translocationの予防と治療               
    May 1995, [Reviewed]
  • DETRIMENTAL EFFECTS OF A NITRIC-OXIDE SYNTHASE INHIBITOR (N-OMEGA-NITRO-L-ARGININE-METHYL-ESTER) IN A MURINE SEPSIS MODEL
    K FUKATSU; H SAITO; R FUKUSHIMA; T INOUE; MT LIN; T INABA; T MUTO
    ARCHIVES OF SURGERY, Apr. 1995, [Reviewed]
  • バクテリアルトランスロケーション               
    Feb. 1995, [Reviewed]
  • サイトカインと栄養 重症感染症               
    Feb. 1995, [Reviewed]
  • 栄養投与ルートと生体反応               
    Feb. 1995, [Reviewed]
  • 臓器障害とNitric Oxide
    Jan. 1995, [Reviewed]
  • 救急Now 多臓器不全の栄養管理               
    Nov. 1994, [Reviewed]
  • 外科領域における集中管理の進歩 術後感染症の予防               
    Sep. 1994, [Reviewed]
  • 生体反応の新しい制御法 周術期栄養管理               
    Sep. 1994, [Reviewed]
  • 集中治療と輸液・栄養 重症感染症と輸液・栄養管理               
    Aug. 1994, [Reviewed]
  • 外科侵襲時のBacterial Translocationの意義               
    Aug. 1994, [Reviewed]
  • 臨床医からみた病院感染対策の実際 消化器外科における術後感染対策               
    May 1994, [Reviewed]
  • TIME-COURSE OF PRODUCTION OF CYTOKINES AND PROSTAGLANDIN E(2) BY MACROPHAGES ISOLATED AFTER THERMAL-INJURY AND BACTERIAL TRANSLOCATION
    R FUKUSHIMA; JW ALEXANDER; JZ WU; JX MAO; K SZCZUR; AM STEPHENS; JD OGLE; CK OGLE
    CIRCULATORY SHOCK, Mar. 1994, [Reviewed]
  • ICUにおける栄養管理と免疫 脂質代謝と免疫               
    Mar. 1994, [Reviewed]
  • ROLE OF EARLY ENTERAL FEEDING AND ACUTE STARVATION ON POSTBURN BACTERIAL TRANSLOCATION AND HOST-DEFENSE - PROSPECTIVE, RANDOMIZED TRIALS
    L GIANOTTI; JW ALEXANDER; JL NELSON; R FUKUSHIMA; T PYLES; CL CHALK
    CRITICAL CARE MEDICINE, Feb. 1994, [Reviewed]
  • ISOLATED PULMONARY INFECTION ACTS AS A SOURCE OF SYSTEMIC TUMOR-NECROSIS-FACTOR
    R FUKUSHIMA; JW ALEXANDER; L GIANOTTI; CK OGLE
    CRITICAL CARE MEDICINE, Jan. 1994, [Reviewed]
  • THE PRIMARY SITE OF BACTERIAL TRANSLOCATION
    R FUKUSHIMA; L GIANOTTI; JW ALEXANDER; CL WELLS
    ARCHIVES OF SURGERY, Jan. 1994, [Reviewed]
  • 術後感染症の現況               
    Jan. 1994, [Reviewed]
  • 消化器外科とサイトカイン 臓器不全とサイトカイン               
    Dec. 1993, [Reviewed]
  • 結腸栄養法 最近の進歩               
    Nov. 1993, [Reviewed]
  • 外科病棟におけるMRSA感染とその対策               
    Nov. 1993, [Reviewed]
  • 外科と社会(31)外科と院内感染               
    Oct. 1993, [Reviewed]
  • Insulin-like Growth Factor 1投与による術後蛋白代謝改善効果 dose responseを中心に               
    Oct. 1993, [Reviewed]
  • 経腸栄養法 最近の進歩               
    Oct. 1993, [Reviewed]
  • 重症患者の栄養管理 栄養管理の実際 病態別栄養管理 重症感染症               
    Oct. 1993, [Reviewed]
  • PROSTAGLANDIN-E(1) ANALOGS MISOPROSTOL AND ENISOPROST DECREASE MICROBIAL TRANSLOCATION AND MODULATE THE IMMUNE-RESPONSE
    L GIANOTTI; JW ALEXANDER; T PYLES; R FUKUSHIMA; GF BABCOCK
    CIRCULATORY SHOCK, Aug. 1993, [Reviewed]
  • TRANSLOCATION OF CANDIDA-ALBICANS IS RELATED TO THE BLOOD-FLOW OF INDIVIDUAL INTESTINAL VILLI
    L GIANOTTI; JW ALEXANDER; R FUKUSHIMA; CP CHILDRESS
    CIRCULATORY SHOCK, Aug. 1993, [Reviewed]
  • 経腸栄養法               
    Aug. 1993, [Reviewed]
  • 侵襲と生体反応 感染に対する生体反応               
    Aug. 1993, [Reviewed]
  • IDENTIFICATION OF THE BLOOD COMPONENT RESPONSIBLE FOR INCREASED SUSCEPTIBILITY TO GUT-DERIVED INFECTION
    L GIANOTTI; T PYLES; JW ALEXANDER; R FUKUSHIMA; GF BABCOCK
    TRANSFUSION, Jun. 1993, [Reviewed]
  • REDUCTION OF BACTERIAL TRANSLOCATION WITH ORAL FIBROBLAST GROWTH-FACTOR AND SUCRALFATE
    L GIANOTTI; JW ALEXANDER; R FUKUSHIMA; T PYLES
    AMERICAN JOURNAL OF SURGERY, Jan. 1993, [Reviewed]
  • THE ACTIVATION OF BONE-MARROW MACROPHAGES 24 HOURS AFTER THERMAL-INJURY
    CK OGLE; XL GUO; JW ALEXANDER; R FUKUSHIMA; JD OGLE; T BILLIAR; A AYALA; RV MAIER
    ARCHIVES OF SURGERY, Jan. 1993, [Reviewed]
  • 術後蛋白代謝障害               
    1993, [Reviewed]
  • 外科侵襲時の小腸粘膜萎縮ーその病態と対策               
    1993, [Reviewed]
  • 臓器不全とサイトカイン               
    Nov. 1992, [Reviewed]
  • IL-1投与イヌにおけるアラニル・グルタミン経静脈投与の末梢骨格筋代謝に対する効果               
    Jun. 1992, [Reviewed]
  • 肝障害患者における間接熱量測定の意義               
    Apr. 1992, [Reviewed]
  • DIFFERENT ROLES OF IL-1 AND TNF ON HEMODYNAMICS AND INTERORGAN AMINO-ACID-METABOLISM IN AWAKE DOGS
    R FUKUSHIMA; H SAITO; K TANIWAKA; T HIRAMATSU; Y MORIOKA; T MUTO; NN ABUMRAD
    AMERICAN JOURNAL OF PHYSIOLOGY, Mar. 1992, [Reviewed]
  • サイトカインの臓器タウリン代謝に及ぼす影響 とくにIL-1による肺のタウリン摂取亢進を中心に               
    Mar. 1992, [Reviewed]
  • MARKED AND PROLONGED DEPRESSION OF FACTOR-XIII AFTER ESOPHAGEAL RESECTION
    H SAITO; R FUKUSHIMA; O KOBORI; N KAWANO; T MUTO; Y MORIOKA
    SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY, 1992, [Reviewed]
  • Role of Cytokines in Hepatic Response to Injury
    Hideaki Saito; Ryoji Fukushima; Yojiro Hashiguchi; Toshiyuki Sumida; Tetsuichiro Muto
    the japanese journal of gastroenterological surgery, 1992, [Reviewed]
  • インターロイキン-1持続投与下の臓器アミノ酸代謝に及ぼすアラニルグルタミンの効果               
    Nov. 1991, [Reviewed]
  • 感染症とサイトカイン               
    Aug. 1991, [Reviewed]
  • 成長ホルモン併用経静脈栄養による術後の電解質バランスと蛋白代謝               
    1991, [Reviewed]
  • IL-1投与イヌにおけるAla-Glu経静脈投与の効果:とくに臓器乳酸代謝を中心に               
    1991, [Reviewed]
  • 術後生体反応における肝アミノ酸・蛋白代謝の役割 とくに肝蛋白合成のreprioritizationを中心に               
    Sep. 1990, [Reviewed]
  • IL-1の全身および腹腔領域の血行動態に及ぼす影響 開腹術後意識下犬におけるhyperdynamic stateの惹起               
    Jul. 1990, [Reviewed]
  • 救急医療の実際 MRSA感染症               
    May 1990, [Reviewed]
  • 成長ホルモン投与による消化器術後の細胞性免疫能賦活効果とその機序ー胃切除ラットにおける検討を中心にー               
    1990, [Reviewed]
  • 消化器術後の全身蛋白代謝における投与カロリーと成長ホルモン投与の関連               
    1990, [Reviewed]
  • 糖負荷併用間接熱量測定からみた肝障害併存患者の術前後の糖代謝               
    1990, [Reviewed]
  • 高カロリー輸液にヒト成長ホルモンを併用した重症腹膜炎の1経験例               
    1990, [Reviewed]
  • 急性臓器不全の救急処置ーMOF               
    Oct. 1989, [Reviewed]
  • 肝硬変ラットの術後創傷治癒遅延とその機転について               
    Sep. 1989, [Reviewed]
  • 術後早期・安定期における経腸および経静脈栄養法の動的アミノ酸・蛋白代謝に及ぼす影響               
    Sep. 1989, [Reviewed]
  • 術後早期・安定期における経腸及び経静脈栄養法の動的アミノ酸、蛋白代謝に及ぼす影響               
    1989, [Reviewed]
  • 蛋白代謝 rapid turnover protein による肝障害併存手術患者の栄養評価               
    1989, [Reviewed]
  • Emergency room thoracotomyにより救命し得た鈍的右室破裂の1例               
    Dec. 1987, [Reviewed]

MISC

Books and other publications

  • 消化器疾患 最新の治療 2019-2020               
    Contributor
    Mar. 2019
  • 標準外科学 第15版               
    Contributor
    Jan. 2019
  • すべての診療科で役立つ 栄養学と食事・栄養療法               
    Contributor
    Jan. 2019
  • 消化管吻合法バイブル               
    Contributor
    Dec. 2018
  • 一般社団法人日本静脈経腸栄養学会 静脈経腸栄養テキストブック               
    Contributor
    Mar. 2017
  • やさしい がん患者の代謝と栄養管理~病態の変化にそった実践法~               
    Contributor
    Jan. 2017
  • 新体系看護学全書〈別巻〉治療法概説               
    Contributor
    Dec. 2016
  • 癌と臨床栄養 2版               
    Contributor
    Sep. 2016
  • メディカルスタッフのための臨床医学               
    Joint work
    Aug. 2016
  • 術後ケアとドレーン管理のすべて               
    Joint work
    Jul. 2016
  • 感染症 最新の治療2016-2018               
    Contributor
    Apr. 2016
  • 今日の治療薬 2016               
    Contributor
    Jan. 2016
  • 外来診療・栄養指導に役立つ 胃切除後障害診療ハンドブック               
    Contributor
    Jul. 2015
  • 消化器外科学レビュー 2015-‘16               
    Contributor
    Apr. 2015
  • 今日の治療薬 2015               
    Contributor
    Jan. 2015
  • 循環器内科医のための非心臓手術必須知識               
    Joint work
    Jan. 2015
  • 重症患者の治療の本質は栄養管理にあった!               
    Contributor
    Nov. 2014
  • がん患者輸液栄養療法               
    Contributor
    Sep. 2014
  • 栄養管理をマスターする 代謝の理解はなぜ大事?               
    Contributor
    Jul. 2014
  • 今日の治療薬 2014               
    Contributor
    Jan. 2014
  • 敗血症(セプシス) 救命治療の最前線               
    Contributor
    Jan. 2014
  • 胃を切った方の快適な食事と生活のために               
    Contributor
    Nov. 2013
  • 改訂2版 医療関連感染対策なるほど!ABC               
    Contributor
    Jul. 2013
  • 標準外科学 第13版               
    Contributor
    Mar. 2013
  • 今日の治療薬 2013               
    Contributor
    Jan. 2013
  • Nutritional Oncology               
    Contributor
    Nov. 2012
  • 感染症のチーム医療 専門医の処方意図を探れ!               
    Contributor
    Nov. 2012
  • 周術期感染管理テキスト               
    Contributor
    Nov. 2012
  • 重症患者と栄養管理Q&A 第3版               
    Contributor
    Nov. 2012
  • JAID/JSC 感染症治療ガイド2011               
    Contributor
    Mar. 2012
  • 今日の治療薬 2012               
    Contributor
    Jan. 2012
  • キーワードでわかる 臨床栄養 改訂版               
    Contributor
    Aug. 2011
  • 徹底ガイド 胃ろう(PEG)管理 Q&A               
    Contributor
    Jul. 2011
  • 静脈経腸栄養ハンドブック               
    Contributor
    Jun. 2011
  • 輸液・栄養レファレンスブック 決定版               
    Editor
    Apr. 2011
  • 今すぐ実践したい手術着管理と抗菌薬適正使用               
    Contributor
    Mar. 2011
  • 今日の治療薬 2011               
    Contributor
    Feb. 2011
  • 癌と臨床栄養               
    Contributor
    Nov. 2010
  • 消化器外科学レビュー               
    Contributor
    Apr. 2010
  • 重症患者と栄養管理Q&A 改訂版               
    Contributor
    Feb. 2010
  • 今日の治療薬 2010               
    Contributor
    Feb. 2010
  • 「治る力」を引き出す 実践!臨床栄養               
    Contributor
    Jan. 2010
  • 慢性期医療認定講座テキス ト 慢性期の医療と看護のポイント解説               
    Contributor
    Jun. 2009
  • ケースで学ぶ栄養管理の思考プロセス 第1巻 消化管・消化器疾患               
    Contributor
    Jun. 2009
  • 胃癌術式と胃術後障害-そのコンセンサスの現状と解説               
    Contributor
    Mar. 2009
  • 今日の治療薬 2009               
    Contributor
    Feb. 2009
  • NST完全ガイド・改訂版 経腸栄養・静脈栄養の基礎と実践               
    Contributor
    Jan. 2009
  • 医療関連感染対策なるほど!ABC               
    Contributor
    2008
  • コメディカルのための静脈経腸栄養ハンドブック               
    Contributor
    2008
  • 全科に必要な栄養管理Q&A-初歩的な知識からNSTの実際まで- 改訂版               
    Contributor
    2008
  • キーワードでわかる臨床栄養               
    Contributor
    Jul. 2007
  • 経腸栄養バイブル               
    Contributor
    2007
  • よくわかって役に立つ 最新 栄養予防治療学               
    Contributor
    Jan. 2007
  • 新臨床外科学 第4版               
    Contributor
    2006
  • 周術期感染対策マニュアル 抗菌薬使用から周術期管理まで               
    Contributor
    2006
  • 別冊・医学のあゆみ 消化器疾患 -state of arts               
    Contributor
    2006
  • 全科に必要な栄養管理Q&Aー初歩的な知識からNSTの実際までー               
    Contributor
    2005
  • 手術部位感染(SSI)対策の実践               
    Contributor
    2005
  • NST完全ガイド 栄養の基礎と実践               
    Contributor
    2005
  • 各科に役にたつ救急処置・処方マニュアル               
    Contributor
    2005
  • 小腸機能からみた経腸栄養ハンドブック               
    Contributor
    2004
  • NSTガイドブック               
    Contributor
    2004
  • 消化器病診療ー良きインフォームド・コンセントに向けてー               
    Joint work
    2004
  • 消化器外科周術期のすべて               
    Joint work
    2003
  • 消化管疾患の薬物療法               
    Joint work
    2003
  • 病院感染対策なるほどABC               
    Joint work
    2003
  • 日本外科感染症研究第15巻               
    Joint work
    2003
  • 専門医のための消化器外科学レビュー2002               
    Joint work
    2002
  • ナースの外科学 改訂第3版               
    Joint work
    2002
  • 日本外科感染症研究第14巻               
    Joint work
    2002
  • 集中医療医学               
    Joint work
    2001
  • 国試必修シリーズ プライマリケア/主要症候 改訂第2版               
    Joint work
    2001
  • n-Books 8 経静脈・経腸栄養のすべて               
    Contributor
    2001
  • 標準集中治療医学               
    Contributor
    2000
  • 日本外科感染症研究第12巻               
    Joint work
    2000
  • 国試必修シリーズ プライマリケア/主要症候               
    Joint work
    1999
  • 新臨床外科学第3版               
    Contributor
    1999
  • 外科分子病態学               
    Joint work
    1999
  • 敗血症の新しい展開               
    Joint work
    1998
  • 日本外科感染症研究第10巻               
    Joint work
    1998
  • 臨床侵襲学               
    Contributor
    1998
  • The immune consequences of trauma, shock and sepsis-mechanisms and therapeutic approaches-Volume 2               
    Lin MT; Saito H; Fukushima R; Inoue T; Fukatsu K; Inaba T; Muto T; Inoue T; Saito H; Fukushima R; Fukatsu K; Lin MT; Inaba T; Muto T, Joint work, ① Parenteral vs Enteral Nutrition: Different Host Responses to Infection ②Growth hormone improves survival in a murine model of gram-negative sepsis
    Pabst Science Publishers, 1997
  • ベッドサイド管理のてびき               
    Contributor
    1997
  • イラストレイテッド外科ベーシックサイエンス               
    Contributor
    1996
  • The immune consequences of trauma, shock and sepsis-mechanisms and therapeutic approaches               
    Fukatsu K; Saito H; Fukushima R; Inoue T; Lin MT; Inaba T; Muto T, Joint work, nhibition of nitric oxide synthase is detrimental in a mouse model of sepsis
    Pabst Science Publishers., 1996
  • 術前術後の輸液栄養管理               
    Joint work
    1995
  • 臓器障害因子とその周辺               
    Joint work
    1994
  • グルタミンのすべて               
    Joint translation
    1994
  • 日本外科感染症研究第6巻               
    Joint work
    1994
  • 日本外科感染症研究第3巻               
    Joint work
    1991
  • 日本外科感染症研究第2巻               
    Joint work
    1990
  • 日本外科感染症研究第1巻               
    Joint work
    1989

Lectures, oral presentations, etc.

Affiliated academic society

  • JAPAN SOCIETY FOR BIOLOGICAL THERAPY               
  • INTERNATIONAL GASTRIC CANCER ASSOCIATION               
  • INTERNATIONAL SOCIETY OF SURGERY               
  • SURGICAL INFECTION SOCIETY               
  • EUROPEAN SOCIETY FOR CLINICAL NUTRITION AND METABOLISM               
  • AMERICAN SOCIETY FOR PARENTERAL AND ENTERAL NUTRITION               
  • THE JAPAN SOCIETY OF ADULT DISEASES               
  • JAPANESE SOCIETY OF CHEMOTHERAPY               
  • THE JAPANESE ASSOCIATION FOR INFECTIOUS DISEASES               
  • JAPANESE COLLEGE OF SURGEONS               
  • JAPAN SOCIETY FOR SURGICAL INFECTION               
  • JAPAN SOCIETY FOR ENDOSCOPIC SURGERY               
  • THE JAPAN ESOPHAGEAL SOCIETY               
  • JAPANESE GASTRIC CANCER ASSOCIATION               
  • JAPAN SOCIETY OF CLINICAL ONCOLOGY               
  • JAPANESE SOCIETY FOR PARENTERAL AND ENTERAL NUTRITION               
  • JAPANESE SOCIETY FOR ABDOMINAL EMERGENCY MEDICINE               
  • JAPANESE SOCIETY FOR SURGICAL METABOLISM AND NUTRITION               
  • JAPAN SURGICAL ASSOCIATION               
  • JAPAN GASTROENTEROLOGICAL ENDOSCOPY SOCIETY               
  • JAPANESE SOCIETY OF GASTROENTEROLOGY               
  • THE JAPANESE SOCIETY OF GASTROENTEROLOGICAL SURGERY               
  • JAPAN SURGICAL SOCIETY               

Research Themes

  • Development of trocar-type operation guidance device for avoiding dangerous operating of forceps
    Grant-in-Aid for Scientific Research (C)
    Teikyo Heisei University
    01 Apr. 2021 - 31 Mar. 2024
  • Early stage diagnosis of gastric cancer by plasma microRNA and tumor-free DNA
    Grant-in-Aid for Scientific Research (C)
    Teikyo University
    01 Apr. 2017 - 31 Mar. 2022
    The prognosis of gastric cancer (GC) patients with advanced stage is still poor. Nivolumab has been used for metastatic GC in Japan from 2017 as an immunotherapeutic agent. Nivolumab can block the binding between PD-1 of lymphocyte and PD-L1/PD-L2 of tumor cell. However, the prognostic predicting role of PD-L1/PD-L2 expression is not clear. Thus, the aim of this investigation was to look at the correlation between the PD-L1/PD-L2 and clinicopathological factors of GC patients.
    The expression of PD-L1/PD-L2 in the serum and tumor tissue of 242 GC patients who underwent surgery were analyzed. The expressions of PD-L1/PD-L2 in the serum were higher than those of normal control. There was no significant correlation between the expression of PD-L1/PD-L2 in the serum and tumor tissue of gastric cancer patients and clinicopathological factors and of patients’ survival.
    It is concluded that the expression of PD-L1/PD-L2 in gastric cancer patients was not estimated as prognostic factor.
  • Development of peritoneal recurrence prediction and therapeutic effect diagnosis in gastric cancer patients
    Grant-in-Aid for Scientific Research (C)
    Teikyo University
    01 Apr. 2013 - 31 Mar. 2016
    Early diagnosis of peritoneal dissemination in gastric cancer patients is important because of the high recurrence rate of this disease. In this study, we examined the usefulness of a peritoneal recurrence genetic diagnosis panel (gene panel) consisting of cancer stem cell and cancer specific markers for gastric cancer (GC). The study was examined the peritoneal lavage fluid of 470 GC patients. The Peritoneal recurrence free survival of the gene panel positive group was significantly worse than that of the gene panel negative group. Genetic markers were independent prognostic factors for peritoneal recurrence. In patients administered with chemotherapeutic drugs (Paclitaxel), the result of the gene panel showed a significant association with peritoneal dissemination. Our results indicate that the newly developed gene panel is a useful tool in the early diagnosis of GC and effective monitoring of the therapeutic effects of chemotherapy in GC patients.
  • Making a model of digestive tract infection and carcinogenisis of Epstein-Barr virus produced by epithelial cell line (GTC) derived from human gastric adenocarcinoma.
    Grant-in-Aid for Scientific Research (C)
    Teikyo University
    2004 - 2005
    Epstein-Barr virus (EBV) has been implicated in the pathogenesis of some type of gastric adenocarcinoma. We established an epithelial cell line (GTC-4) derived form human gastric cancer tissue. The cell line have a capacity of producing EBV. We further cloned EBV producing cell line GTC-5 from GTC-4 cells and found that digestive tract of Balb/c mice can be infected by EBV produced by GTC-5 (GTC-5-EBV) and finally infected mice developed adenocarcinoma of the digestive tract.
    Balb/c mice were gavaged with 0.2ml of 50% ethanol to produce gastric mucosal injury and than GTC-5-EBV were gavaged. Histoimmunostaining showed that EBV nuclear antigen NA-2 were positive in the gastric mucosa 24 hours after the gavage of EBV and disappeared in 21 days. NA-1 and LMP-1 (latent membrane protein 1) were also present in gastric mucosa 5 days after the gavage and disappeared 6 months later. EBER (EBV-encoded small RNA) were identified in the gastric mucosa by in situ hybridization 24 hours after the gavage and it lasted for 9 months. EBER positive adenocarcinoma were developed in the stomach 9 months after the gavage of EBV.
    In the next experiment, Balb/c nude mice (6-7W and 10 month, n=10 each) were used to evaluate the carcinogenesis of GTC-5-EBV. GTC-5-EBV was injected weekly for 8 times. After 4 months, adenocarcinoma were found in the rectum of 100 % of elderly mice. In contrast, no cancer was found in the young mice during the observation period of 6 months.
    Our model of EBV associated carcinogenisis of digestive tract seems useful in studying the etiology and treatment of EBV associated disorders.
  • Role of Gut after severe surgical stress
    Grant-in-Aid for Scientific Research (C)
    Teikyo University
    1997 - 1999
    Experiment I
    Sepsis that follows severe trauma often results in multiple system organ failure (MSOF) and death. The sequential nature of this clinical picture has led to the idea of a "two-hit" or "second attack" theory for the development of MSOF. We investigated bacterial translocation (BT) and cytokine responses in a rat second attack model and see if the timing and route of nutrition supply can modulate these responses.
    Methods: Rats (n=57) underwent midline laparotomy and were postoperatively challenged I.p. with zymosan as a second attack. Animals were divided into S1 (zymozan on POD1) and S3 (zymozan on POD3) group and each group of rats were further divided into TPN (total parenteral nutrition) group, TEN (total enteral nutrition) group and C (chow) group. After laparotomy TPN and TEN rats received isocaloric and isonitrogenous nutrition. Rats in C group were provided standard rat chow ad libitum. Eighteen hours after zymosan challenge, rats were gavaged with 108 E. coli and sacrificed four hours later. Liver, mesenteric lymphnode (MLN), spleen and blood were harvested. BT and cytokine levels in the organs were determined.
    Results <>
    Early occurrence of postoperative second attack (S1) resulted in higher incidence of bacterial translocation and u regulated IL-6 response than in the late occurrence of second attack (S2), Nutrition supply by enteral route decreased translocation of bacterial and IL-6 production.
    Conclusion: Nutrition supply by enteral route appeared to be most useful in the early postoperative course when the occurrence of second attack may cause serious consequences.
    Experiment II
    On the basis of experiment I, post operative early enteral nutrition was performed to those underwent total gastrectomy or subtotal esophagectomy. Enteral nutrition was initiated in 26 patients within 24 hours after surgery. In the initial 12 patients, 300 kcal/day was administered on POD 1 and 2, 600 kcal/day on POD 3 and 4, 1200 kcal/day after POD 5. Enteral nutrition was discontinued in two patients on POD 4 and the amount was decreased in two patients on POD 5 because of abdominal distention and/or diarrhea. In the rest of patients, 900 kcal/day was administered after POD 5 and they were well tolerated.
    It is concluded that early enteral nutrition within 24 hours post gastrointestinal surgery was possible in the majority of patients.
  • Disruption of gut barrier function and cytokine responses after severe surgical stress-mechanism and treatment
    Grant-in-Aid for General Scientific Research (C)
    1994 - 1995
    Experimenr I
    Effects of growth hormone (GH) and insulin-like growth factor I (IGF-I) administration on burn induced gut derived sepsis was evaluated. BALB/c mice (n=50) were treated subcutaneously with 4.8mg/kg/day of GH,24mg/kg/day of IGF-I or placebo twice a day for 4 days. Then they were gavaged with 10^<10>E.coli and subjected to 20% full sickness flame burn. All mice received allogeneic blood transfusion 5 days before burn to induce mild immunosuppression. Thirty mice were observed for survival and twenty mice were sacrificed at 20 hours post burn. GH and IGF-I administration reduced the incidence of translocation to MLN and other organs 20 hours post burn and significantly improved survival. We conclude that GH and IGF-I may be useful during critical illness.
    Experiment II
    The previous investigation revealed that bacterial translocation is highly associated with mortality after burn injury. To further clarify the mechanism of bacterial translocation related organ dysfunction and subsequent death, we investigated the relation between the degree bacterial translocation and neutrophil accumulation in the liver.
    Blood transfused Balb/c mice were treated with oral 200mg/kg/day enisoprost (PGEl analog) or saline for three days and then they were gavaged with 10^<10 14>C E.coli and 20% full sickness flame burn was inflicted. According to our previous investigation, these mice have a mortality rate of approximately 80% and enisoprost improved the mortality to up to 30%. Animals were sacrificed 24 hour post burn and mesenteric lymph node (MLN), Liver, and spleen were harvested. Bacterial translocation were determined by both radionuclide count (dpm) and viable colony count in the MLN and Liver. Leukocyte accumulation was evaluated by the measurement of myeloperoxidase (MPO) in the liver. Consistent to previous work, enisoprost significantly reduced the translocation. MPO in the liver was significantly greater in the control group compared to enisoprost group. There was a significant correlation between MPO and the degree of bacterial translocation (p<0.05). It can concluded that bacterial translocation enhanced neutrophil accumulation in the liver which may be the cause of organ injury after burn injury.
    Experiment III
    Using the same model as experiment II,splenic macrophages were separated and cultured for 24 hours with and without 10mcg/ml of LPS.TNF,IL-1 IL-6 and PGE2 in the cell culture supernatants were measured. LPS stimulated macrophage production of IL-1, IL-6 and PGE2 were significantly greater in enisoprost treated animals. It is likely that prior lack of in vivo maximal stimulation of macrophages in the enisoprost treated animals can produce greater amounts of cytokines when further stimulated with LPS in vitro.
  • Reconstruction after Gastrectomy               
  • Bacterial Translocation during Surgical Stress               
  • Perioperative Nutrition Support for Surgical Patients               
  • ■University education and qualification information

    Qualifications, licenses

    • 01 May 1983